A recently published size research report by Fact.MR on the Preimplantation Genetic Testing Size depicts a crystal clear view of the size over the considered period of assessment (2017 2022). The global preimplantation genetic testing size study comes with an all in all compilation of the future, existing, and historical outlook of the size as well as the factors bringing in such growth for the size. With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities, and threats of each preimplantation genetic testing size player in a comprehensive way. Further, the preimplantation genetic testing size report emphasizes the adoption pattern of the preimplantation genetic testing across various industries.

The existing trends, restraints, opportunities, and size drivers are studied thoroughly to offer a clear, 360-degree understanding of the existing landscape prevailing in the preimplantation genetic testing size. The research paints a detailed picture of how the size is likely to take shape in the coming years given the influence of current drivers, opportunities, and restraints. In this latest size research study published by Fact.MR, the analysts have taken into account the preimplantation genetic testing size from a local as well as global viewpoint.

Act Today to Succeed Tomorrow, Know the COVID-19 Impact, Request for Sample @https://www.factmr.com/connectus/sample?flag=S&rep_id=292

The outbreak of novel coronavirus across the globe has changed the way about how we do business, it has resulted in both disadvantages and advantages for players operating in the preimplantation genetic testing size. A health crisis of enormous proportion, COVID-19 has emerged as a pandemic that would cause a restructuring of the world economy as well as social order. This outbreak is clearly going to characterize the coming era with fundamental schism. Many companies have shifted from their traditional methods of advertising during the lockdown period.

Taking help of this latest offering on the preimplantation genetic testing size by Fact.MR, the size players, suppliers, distributors, and other stakeholders can formulate innovative strategies based on their understanding of the pandemic and our report to expand their business and widen their base of customers. This research study by Fact.MR is likely to detail the factors that could impact the sales of products/ services in the global size landscape. The report is also likely to suggest avenues of growth that could boost sales in the post-pandemic era.

According to the size research report, the preimplantation genetic testing size is estimated to register a CAGR growth of 8.4% over the assessment period due to several key factors that is likely to influence the size, such as favorable regulatory policies, augmented spending on research and development. The analysts at Fact.MR makes use of the latest research methodologies while gathering data from credible and reliable sources, both primary and secondary, to prepare and present the size study.

In this preimplantation genetic testing size study, the following years are considered to project the size footprint:

The preimplantation genetic testing size report has answers to important questions, which include the following:

The preimplantation genetic testing size report covers the following regions:

On the basis of product type, the preimplantation genetic testing size report considers the following segments:

On the basis of end-use, the preimplantation genetic testing size report includes:

Ask for Regional Data of This Report @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=292

Prominent preimplantation genetic testing size players covered in the report contain:

The behavioral pattern of each of the size player, such as acquisitions, new product launches, partnerships, and mergers have been thoroughly studied to offer a detailed view of the competitive landscape of the preimplantation genetic testing size.

Contact:

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai, United Arab Emirates

SIZE ACCESS DMCC Initiative

Email: sales@factmr.com

Web: https://www.factmr.com/

Press Release:

Here is the original post:
Preimplantation Genetic Testing Size Size to Expand Lucratively during the Forecast Period 2017-2022 - The Cloud Tribune

Recommendation and review posted by Bethany Smith

(UroToday.com) Since 2015, multiple studies together have suggested that approximately a quarter of metastatic castration-resistant prostate cancer (mCRPC) tumors have mutations in DNA damage repair (DDR) genes. These alterations, especially those in genes for homologous recombination repair (HRR), are associated to varying degrees with response to PARP inhibitor therapy. Two PARP inhibitors are now approved for the care of patients with mCRPC and mutations in certain HRR genes: olaparib (based on PROfound trial) and rucaparib (based on TRITON2 trial). Given the significance of alterations in HRR genes in mCRPC, genomic testing for HRR alterations has been included in mCRPC treatment guidelines with the purpose of guiding genetic counseling and therapy selection.

In this poster, Dr. Neal Shore and colleagues describe real-world patterns and predictors of tissue testing for alterations in HRR genes. They focused on the community cancer care setting. Data were collected from the Flatiron Health Electronic Health Record derived database that was collected between 2013 and March 2019, prior to the approval of PARP inhibitor therapy in mCRPC, and focused on testing for alterations in BRCA1, BRCA2, ATM, CDK12, FANCA, and PALB2). The Flatiron database contains information on patient demographics, prostate cancer characteristics, and treatment, as well as genetic testing results.

From the Flatiron database, 5,213 patients with mCRPC were identified, 91% of which were managed at community oncology care centers. Of these patients, 674 (12.9%) underwent testing for the specified HRR gene alterations. Patient characteristics are shown below.

The breakdown of the 674 patients by testing method and number of genes tested is shown below.

BRCA1 and BRCA2 were the most commonly tested genes. A substantial portion of patients underwent only blood/saliva testing (40.5%, capable of detecting germline or circulating tumor DNA) or tumor-tissue testing only (42.1%, capable of detecting germline or tumor tissue DNA alterations). Only 1.8% of patients undergoing blood/saliva testing were tested for all 6 HRR genes, and 69% of tumor-tissue testing covered all 6 genes. Amongst the 286 patients who had negative blood/saliva testing, only 12.6% underwent tumor-tissue profiling, and 5 of these patients (13.9%) had an HRR alteration found.

The most common testing platform utilized was Foundation Medicine, followed by Guardant. Testing rates and the inclusion of more genes increased with time.

The prevalence of HRR alterations found is shown below.

Treatment at an academic medical center or having received multiple prior lines of therapy was associated with a higher likelihood of having HRR mutational profiling. Older age and higher PSA value at diagnosis of mCRPC were significantly associated with a lower likelihood of HRR mutation profiling.

The poster concludes that rates of HRR mutational testing did not increase dramatically with changes to the NCCN guidelines recommending this testing in 2017. Increased awareness of recommendations for testing, especially with the approval of two therapeutic agents contingent upon the presence of HRR alterations, is critical for the care of patients with mCRPC.

Presented by: Neal Shore, MD FACS, Urologist, and Director of the Carolina Urologic Research Center, Myrtle Beach, South Carolina

Written by: Alok Tewari, MD, Ph.D., Medical Oncologist at the Dana-Farber Cancer Institute, at the 2020 European Society for Medical Oncology Virtual Congress (#ESMO20), September 19th-September 21st, 2020

Excerpt from:
ESMO Virtual Congress 2020: Real-World Patterns of Genomic Testing in Patients with Metastatic Castration-R... - UroToday

Recommendation and review posted by Bethany Smith

As per a report Market-research, the Genealogy Products and Services economy is likely to see a CAGR increase of XX% within the forecast period (2019-2029) and reach at a value of US$ at the ending of 2029. The macro economic and micro elements which are predicted to influence the trajectory of this market are examined from the market analysis that was presented.

Light onto the material throws Providers, vendors, manufacturers, and market participants at the value string of their industry that is Genealogy Products and Services . Whats more, its particular influence on the market and the political and economic scenarios of regions are discussed within the analysis.

Critical Details included from this record:

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=3083

Competitive Outlook

Light onto the throws Business prospects of players operating from the industry that is Genealogy Products and Services . The item pricing plans, marketing stations that were preferred and product portfolio of most players, and promote presence of every and every provider is contained in the title. The players comprise Business 4, Business two, Business 3, and Business.

Regional Assessment

The marketplace research that is introduced sheds light onto the Marketplace Scenario in numerous markets. Additionally, the effects of the governmental and regulatory policies to this market in every regions prospects is examined from the report.

competitive landscape, get in touch with our experts

Demand for Genetic Testing to Surge as Preventive Healthcare and Pharmacogenomics Gain Traction

Preventive healthcare is gradually gaining center stage with consumers becoming increasingly aware of the benefits of the practice. Genetic testing plays a vital role in preventive healthcare as it provides a potential technique for diagnosis of rare diseases. It is showing promising prospects for precisely predicting the risk of developing a particular disease by studying the complex genetic markup of the population.

Numerous researchers claiming the efficacy of genetic testing are promoting its adoption. The procedure can potentially enable doctors to suggest measures to prevent the development of a certain health condition. Investments by governments are further fueling the growth of the genealogy products & services market. For instance, the National Health Service in England recently announced its plan to expand genetic testing capabilities to improve the quality of health services in the country.

Development of pharmacogenomics is another factor imperative to genealogy products & services market growth. Pharmacogenomics is the study of genetics to predict the impact of medication on the human body. Genetic testing is already being leveraged for prescribing personalized medications in the treatment of panic disorder, anxiety, schizophrenia, bipolar disorder, and post-traumatic disorder.

For detailed analysis on all the key market factors, request a sample

Genealogy Service Providers Widening the Scope of Application

Genealogy products & services providers are foraying into an assortment of different verticals to extend their consumer base. Use of genealogy and genetic testing for offering personalized services in a multitude of markets is gradually gaining traction. Companies such as EpigenCare and SkinGenie are leveraging genetic testing to provide skin care products that particularly complement the genetic makeup of a persons skin. On the other hand, Pheramor, a company based in Houston, is using genetic testing for finding people their compatible partners. Another example of the widening scope of genealogy products & services is Vinome, a company which provides a thorough report of the different wines a person may have an affinity for after studying their genetic makeup.

Aggressive marketing techniques, coupled with growing consumer inquisitiveness about such implications of genealogy, is aiding these applications in gaining popularity which, in turn, is expected to bolster genealogy products & services market growth.

Technological Innovations Complementing Market Growth

Genealogy products & services market is estimated to benefit from headways in technology. Genealogy products & services companies are harnessing data analytics, machine learning, big data, and artificial intelligence for effectively storing and analyzing a large amount of data. Genealogy products and services companies are increasingly using online platforms for marketing their services and increaing penetration into the market.

Enhanced DNA sequencing technology is further helping companies in analyzing genetic sequences at a faster rate and affordable costs while providing them accurate results. For instance, scientists in Estonia were successfully able to develop a genetic testing technology which analyzes genes at single-molecule level, paving way for enhancing the efficacy of precision medicines at lower costs. Other factors such as the development of sophisticated infrastructure for efficient sharing of huge DNA datasets is estimated to bolster genealogy products & services market growth.

Data Confidentiality Continues to Pose Challenges

The current status-quo in the genealogy products andservices market involves digital storage of data exposing it to the dangers of cybercrime and hacking. Additionally, genetic testing also influences life insurance premiums with companies considering results from the process to determine premiums. Insurance companies in Australia include genetic tests results in the risk classification for underwriting and are allowed to deny insurances in case the results predict the development of life-threatening diseases in the future. Further, the procedure can potentially cause discrimination during employment with the employers denying applications on the possibility of an applicant developing a disability in the future. Although the law prohibits companies from doing so, illegal leaking of information can influence the process.

While registering for genealogy processes, consumers compulsorily need to provide valuable information such as credit card numbers, name, and email addresses. This makes the companies a favorite target of cybercriminals. In addition to this, the increasing instances of data breaches are estimated to discourage consumers from using the services. Presence of lax or no regulations for classifying genetic testing as effective is adding to consumers confusion and poses a vital challenge to the genealogy products & services market growth.

Definition

Genealogy is the study of heritages and lineages, and comprises lineage tracing, DNA testing, cemetery records, family tree creation, and other related services.

About the Report

The report on genealogy products and services market provides an all-inclusive assessment of all the factors influencing the genealogy products & services market. Additionally, the report on genealogy products & services market provides a qualitative and quantitative assessment of each of the factors identified. The report also includes an opportunity assessment of the genealogy products & services market. An assessment of the competitive landscape prevalent in the genealogy products & services market has also been included in the report.

Market Structure

The report on genealogy products andservices market segments the genealogy products & services market on the basis of category and region. Based on the category, the genealogy products & services market can be segmented into family records, family tree, forum, cemetery, newspapers, blogs, links, and DNA testing.

Additional Questions Answered

In addition to the aforementioned insights about the genealogy products & services market, the report answers the following vital questions about the genealogy products andservices market:

Research Methodology

The report on genealogy products & services market is a consequence of robust and exhaustive research methodology. A two-step research process was employed to obtain insights into the genealogy products andservices market. Interviewing experts from the genealogy products & services market formed the basis of primary research while secondary research was conducted by thoroughly studying genealogy products & services trade journals, paid sources, and other industry-related publications. Results from both the steps were triangulated to produce an accurate forecast of the genealogy products andservices market.

Request methodologyof this Report.

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=3083

The report Suits the questions pertaining Into the Genealogy Products and Services economy:

Reasons Fact.MR Sticks out

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=3083

Excerpt from:
Genealogy Products and Services Market Estimated to be Driven by Innovation and Industrialization 2018 to 2024 - The Daily Chronicle

Recommendation and review posted by Bethany Smith

Lufthansa is bringing COVID-19 testing to the airport. Currently being offered by the airline at a handful of German airports, Lufthansa is utilizing a polymerase chain reaction (PCR) test to certify departing and arriving passengers are negative for the coronavirus.

Bjoern Becker, senior director product management ground and digital, Lufthansa, said Tuesday during a virtual press conference, titled Safe Travels with Lufthansa Group in Times of COVID-19, from the outset of the pandemic, the airline knew testing would be key to not only returning air travel back to normal, but getting the virus at large under control.

We said we want to focus on testing and build up test facilities for our guests that make it easy for them to access, Becker said. We integrated it into the experience and it is a fully digitalized service.

When arriving to Germany on a Lufthansa flight, passengers will receive a flyer with links to a dedicated website allowing them to schedule a time and location for the test through the Lufthansa app. Currently, those arriving to Germany must undergo a 14-day quarantine, but can be released early with a negative test result. Passengers who test negative for COVID-19 will also receive a digital certificate from Lufthansa, allowing them to travel freely to countries that require negative tests to enter.

For example, if youre going to China, our gate crew knows how to check the certificate, Becker said. Our aim was our passenger dont have to hassle with that. They dont need to worry too much about that. We make it as easy as possible.

For departing passengers, the process works similarly but they can get a test prior to their flight at their departing airport. PCR tests can take as long as 24 hours to get results, although Becker said that on average results are had between two and four hours. For those willing to wait, they can arrive early at the airport, receive the test then wait in the lounge for the results before their flight. Otherwise, Becker said, it is advisable to go a day early to receive the test.

The PCR tests are free, but Becker said he sees a future where premium passengers can pay to get expedited test results.

The airport testing centers are also open to people not planning to fly and at Lufthansas testing center in Frankfurt, the airline has the capacity to run over 20,000 tests a day, Becker added.

Lufthansa also has testing centers at the Munich Airport. Tests are conducted by CENTOGENE, a rare disease and genetic testing company, who also hosts testing sites off the airports that Lufthansa passengers can utilize through the two entities collaboration.

Becker said testing before flights also can give passengers ease of mind as they fly, knowing that everyone on board the plane has been cleared of the virus.

Its the most protected environment you can be in, he said.

Lufthansa is also sharing the data they collect with the local governments, helping with both contract tracing passengers who later fall ill, and being able to show where upticks in the virus are forming, what countries are most at risk and where ill travelers are arriving from.

Becker said that Lufthansa wants to expand their testing capabilities to more countries, such as the United States. However, the challenge in doing so is twofold.

Lufthansas main concern is having the capacity to perform the tests themselves. If 200 people need to leave for a flight, Lufthansa wants to be able to test all 200 of those people through their own means and not put a strain on a governments outside testing.

We dont want to cannibalize the local or regional testing of a country, Becker said.

The other issue is the time that PCR tests can take. It is not always realistic for people who need to fly immediately to wait hours for test results.

A solution to this problem that Lufthansa officials see is the rise of antigen tests, which can give results in minutes. However, antigen tests are only now hitting the market and no country currently recognizes them as a valid test as to whether an induvial has COVID-19.

Becker said he is hopeful though that antigen testing proves to be reliable and adopted by countries and allow those who are eager to get back into the skies the ability to.

Go here to see the original:
Boarding with a Clean Bill of Health - AviationPros.com

Recommendation and review posted by Bethany Smith

Sept. 22, 2020 18:33 UTC

Next Generation Anti-Androgen as a Potential Treatment for COVID-19

IRVINE, Calif.--(BUSINESS WIRE)-- While studying the genetics of the androgen receptor, a team of scientists discovered a possible breakthrough treatment for COVID-19.

The team led by Andy Goren, MD from Applied Biology, Flavio A. Cadegiani, MD, MSc, PhD from Corpometria Institute in Brazil, along with other collaborators, have published their discovery in several medical journals. The manuscript, What Does Androgenetic Alopecia have to do with COVID-19? An Insight into a Potential New Therapy (doi: 10.1111/dth.13365), elucidates the possible role of androgens in controlling the infectivity of SARS-CoV-2 in human lung cells.

According to Dr. Goren, Our earlier discovery potentially links SARS-CoV-2 infectivity to androgens, the same hormones implicated in male pattern baldness and prostate cancer; thus, anti-androgens originally developed for prostate cancer may prove a breakthrough therapy for COVID-19. One of the most promising anti-androgens is proxalutamide, a next generation anti-androgen.

The study on the effects of proxalutamide on COVID-19 has received national IRB approval and will be conducted in Brasilia, Brazil, in non-hospitalized patients with mild-to-moderate COVID-19 disease. Recruitment of volunteers should start this week.

According to Dr. Cadegiani, We are excited to commence this study that could potentially benefit millions of patients and change the course of COVID-19.

More information about the study (ClinicalTrials.gov Identifier: NCT04446429) is available at clinicaltrials.gov (https://clinicaltrials.gov/ct2/show/NCT04446429?term=NCT04446429&draw=2&rank=1).

The approval was received on September 17th, 2020 from the IRB of the National Board of Ethics Committee (CONEP), from the Brazilian Ministry of Health, under the name The Proxa-AndroCoV Trial, number (CAAE) 36700320.8.0000.0023.

ABOUT APPLIED BIOLOGY

Founded in 2002, Applied Biology, Inc. (www.appliedbiology.com), headquartered in Irvine, California, is a biotechnology company specializing in hair and skin science. Applied Biology develops breakthrough drugs and medical devices for the treatment of androgen mediated dermatological conditions. Applied Biology's R&D pipeline includes a topically applied prophylactic treatment for chemotherapy induced alopecia; a novel diagnostic device that can aid dermatologists in identifying non-responders to topical minoxidil; an adjuvant therapy for non-responders to topical minoxidil; and a novel therapy for female pattern hair loss.

ABOUT CORPOMETIRA INSTITUTE

Corpometria institute was founded in 2013, and is focused on treating, researching and optimizing healthcare of the major unsolved endocrine-related conditions, including patients with obesity, sarcopenia, menopause and andropause, chronic fatigue and burnout, undertrained athletes, and rare metabolic and endocrine diseases.

Corpometria R&D pipeline includes three major clusters: amplifying genetic testing, epigenetic influences and metabolomic analyses of patients with not-fully clarified metabolic and endocrine-related illnesses; development of machine learning and AI-based algorithm for personalized metabolic responses and changes to specific eating, exercising and sleeping characteristics; and full elucidation of endocrine physiology of the sport, including specific hormonal and metabolic responses and adaptations to sports according to intensity, volume, frequency and type of physical activity, and in combination with a variety of nutritional, psychological, social, and sleeping characteristics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200922005939/en/

See the original post here:
Applied Biology and Corpometria Institute Receive National IRB Approval to Study a Potential Breakthrough Therapy for COVID-19 - BioSpace

Recommendation and review posted by Bethany Smith

The global Genetic Testing market reached ~US$ xx Mn in 2020 and is anticipated grow at a CAGR of xx% over the forecast period 2019-2029. In this Genetic Testing market study, the following years are considered to predict the market footprint:

The business intelligence study of the Genetic Testing market covers the estimation size of the market both in terms of value (Mn/Bn USD) and volume (x units). In a bid to recognize the growth prospects in the Genetic Testing market, the market study has been geographically fragmented into important regions that are progressing faster than the overall market. Each segment of the Genetic Testing market has been individually analyzed on the basis of pricing, distribution, and demand prospect for the Global region.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/3175

Some of the major companies dealing in genetic testing market are Abbott Laboratories, BioRad Laboratories, Abbott Molecular Inc., AutoGenomics Inc., Celera Group, PerkinElmer Inc., Quest Diagnostics Inc., ELITech Group, Roche Diagnostics Corp., Applied Biosystems Inc., Roche Molecular Diagnostics Inc., Transgenomic Inc. and others.

Key points covered in the report

Each market player encompassed in the Genetic Testing market study is assessed according to its market share, production footprint, current launches, agreements, ongoing R&D projects, and business tactics. In addition, the Genetic Testing market study scrutinizes the strengths, weaknesses, opportunities and threats (SWOT) analysis.

Report at a discounted price exclusively!!! Purchase before the offer ends!!!

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/3175

What insights readers can gather from the Genetic Testing market report?

The Genetic Testing market report answers the following queries:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/3175

Why Choose Genetic Testing Market Report?

Continued here:
Genetic Testing Market Poised to Grow at a Healthy CAGR of XX% During the Forecast Period2020 - The Market Records

Recommendation and review posted by Bethany Smith

Visit the News Hub

As a participating site, Siteman Cancer Cancer will help examine how COVID-19 is affecting medically underserved populations.

Siteman Cancer Center and Washington University School of Medicine in St. Louis are part of a nationwide collaboration seeking to understand how the COVID-19 pandemic has affected minority and uninsured populations and their access to cancer prevention and treatment.

A consortium of 17 U.S. cancer centers including Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine have come together to better understand the consequences of the COVID-19 pandemic in delaying cancer detection, care and prevention.

The cancer centers are working together with the National Cancer Institute on the impact of the pandemic on the continuum of cancer care from prevention to survivorship. This work will further examine whether differences in demographics impact cancer prevention and control, cancer management and survivorship during the pandemic.

In addition to Siteman, participating cancer centers are: ONeal Comprehensive Cancer Center (Alabama), The Barbara Ann Karmanos Cancer Institute (Michigan), The Ohio State University Comprehensive Cancer Center, Holden Comprehensive Cancer Center (Iowa), University of Colorado Cancer Center, Stephenson Cancer Center (Oklahoma), UC Davis Comprehensive Cancer Center (California), Oregon Health & Science University Knight Cancer Institute (Oregon), Fred Hutchinson/University of Washington Cancer Consortium, University of Virginia Cancer Center, Huntsman Cancer Institute (Utah), Vanderbilt-Ingram Cancer Center (Tennessee), Sylvester Comprehensive Cancer Center (Florida), Markey Cancer Center (Kentucky), The University of Kansas Cancer Center and University of Texas MD Anderson Cancer Center.

As a participating site, Siteman is working on this massive collaboration as a direct response to sobering forecasts from the NCI about cancer care during the COVID-19 pandemic. Officials have warned that the pandemic may have prevented some patients from undergoing much needed screenings and hindered access to procedures that could result in late-stage diagnoses and cancer death. Furthermore, delaying cancer screenings, clinical trials and testing during the pandemic could roll back significant gains made in recent years in reducing cancer deaths.

The COVID-19 pandemic has exacerbated health disparities among minority and uninsured populations, including those related to cancer screening and cancer prevention behaviors, said cancer epidemiologist Bettina Drake, PhD, a professor of surgery at Washington University and a research member of Siteman Cancer Center. In addition, delays in screening lead to increases in diagnoses at later stage disease. This collaborative of cancer centers across the U.S. will evaluate the effect of this pandemic on barriers to cancer screening and cancer risk behaviors across diverse populations. More importantly, this work will lead to the development and implementation of strategies that can be adapted to meet the needs of communities most affected by the pandemic.

Collectively, the cancer centers will ask healthy volunteers and cancer survivors nationwide about their health and well-being during the pandemic. The cancer centers will focus on work and employment, housing/home life, social activities, emotional well-being, physical health, and behavior related to COVID-19 prevention, as well as behaviors such as physical activity and tobacco use that have links to cancer. By complying with current pandemic restrictions, individuals will be contacted by phone, text and social media.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Siteman Cancer Center, ranked among the top cancer treatment centers by U.S. News & World Report, also is one of only a few cancer centers to receive the highest rating of the National Cancer Institute (NCI) exceptional. Comprising the cancer research, prevention and treatment programs ofBarnes-Jewish HospitalandWashington University School of Medicinein St. Louis, Siteman treats adults at six locations and partners withSt. Louis Childrens Hospitalin the treatment of pediatric patients. Siteman is Missouris only NCI-designated Comprehensive Cancer Center and the states only member of the National Comprehensive Cancer Network. Through theSiteman Cancer Network, Siteman Cancer Center works with regional medical centers to improve the health and well-being of people and communities by expanding access to cancer prevention and control strategies, clinical studies and genomic and genetic testing, all aimed at reducing the burden of cancer.

More here:
Cancer centers to address pandemic's impact on cancer prevention, treatment - Washington University School of Medicine in St. Louis

Recommendation and review posted by Bethany Smith

A recently approved agent, burosumab (Crysvita), was better than placebo across a range of efficacy outcomes for 14 predefined subgroups of adults with X-linked hypophosphatemia (XLH), new research shows.

The authors analyzed data from the initial 24-week randomized blinded phase of the pivotal phase 3 trial that led to regulatory approval of this drug in the United States in 2018 for XLH, a rare form of rickets characterized by low serum phosphorus levels, skeletal defects, pain, and stiffness.

As in the main analysis, in the subgroups, among patients who received burosumab, serum phosphorus levels were improved, and outcomes were better on the following measures: Western Ontario and McMaster Universities Arthritis Index (WOMAC) stiffness scale, the WOMAC physical function measure, and the Brief Pain Inventory (BPI), which were the main efficacy outcomes. Improvements were seen for many other outcomes as well.

Maria-Luisa Brandi, MD, Careggi University Hospital, Florence, Italy, presented the new subanalysis during the virtual American Society of Bone and Mineral Research (ASBMR) 2020 annual meeting.

The subgroup results were consistent with the overall trial findings, "showing a favorable direction of effect of burosumab relative to placebo" except for results in patients recruited in Asia and non-White patients; those results were considered inconclusive because there were too few participants in those categories, she told Medscape Medical News,.

Lorenz Hofbauer, MD, scientific chair of the ASBMR meeting, said that the take-away message is that the drug "works to reduce pain and disability" in adults with XLH with more severe/less severe symptoms, and "it provides new hope for many patients suffering from this disease," he told Medscape Medical News.

Burosemab also appears superior to what has previously been considered standard therapy for XLH, phosphate/calcitriol, the experts say.

"The disease prevalence is 1 to 9 in a million," Brandi said. "Undiagnosed adults are treated by the doctor that makes the diagnosis, usually a nephrologist or a rheumatologist or a bone doctor; this depends on the prevalent complications in a given patient. The endocrinologist who treats this patient is the one expert in bone disorders."

Hofbauer noted, however, that "[r]are is relative. If you run a bone clinic, you will see four to five patients with XLH; if you are a regional center, 20 to 30 patients. People with rare disease travel more than 1000 miles to see experts."

The US Food and Drug Administration approved burosumab for use in children and adults with XLH 2 years ago. The European Medicines Agency (EMA) approved it for use in children.

The drug is expected to be approved by the EMA for adults with XLH some time this year, said Hofbauer, who is from Dresden Technical University, Dresden, Germany.

Burosumab is a "game changer" with respect to previous treatments, he stressed.

This study is one of the top five clinical abstracts of the ASBMR meeting, which are selected on the basis of "scientific content/novelty, making a difference in clinical practice," Hofbauer explained. He noted that "new drugs that work are always in the top ranks."

Craig Munns, PhD, who was senior author of a recent review about burosumab, agrees.

"Burosumab is transformative, as it is a paradigm shift in the way we manage XLH," he told Medscape Medical News.

"Standard therapy for children is with oral phosphate and calcitriol, and many adults do not receive any therapy," said Munns, from the University of Sydney, Sydney, Australia.

"Phosphate and calcitriol need to be taken multiple times per day, is an incomplete therapy, and has many complications. Burosumab offers a 2-weekly (children) or 4-weekly (adult) dosing regime with superior outcomes compared to no treatment or phosphate/calcitriol," he emphasized.

"Burosumab is an anti-FGF-23 [antifibroblast growth factor-23] antibody for a rare genetic disease, XLH, in which the gene for PHEX is defective," Hofbauer explained.

"PHEX is an enzyme that clears FGF-23; if it does not work, then FGF-23 accumulates in the body and causes phosphate wasting with wide consequences for bone, muscle, and joints. Burosumab is a smart approach, since it blocks these excessive FGF-23 effects."

Children with XLH have rickets, deformities in the lower skeleton, and short stature, Brandi noted, whereas adults have fractures, pseudofractures, enthesopathy (calcification of joint capsule, tendon insertions, and ligaments), pain, stiffness, and impaired physical function.

However, "treatment with oral phosphate and vitamin D is associated with nephrocalcinosis and hyperparathyroidism," she said.

In the phase 3 trial, 134 adults (aged 18 to 65 years) with XLH were randomly assigned in a double-blind manner to receive either burosumab or placebo for 24 weeks, followed by 24 weeks of open-label burosumab. The patients' serum phosphorus levels were <2.5 mg/dL, and they were experiencing measurable bone/joint pain.

Baseline characteristics were similar for the patients who received placebo (66) and those who received burosumab (68). The mean age of the patients was 40 years; 65% were women; and 81% were White.

The current exploratory analysis examined efficacy outcomes in patients grouped according to the following factors and characteristics: sex; age (41 years or >41 years); race (non-White, White); region (Asia, North America/Europe); baseline WOMAC pain score; WOMAC total pain; WOMAC stiffness; WOMAC physical function; BPI worst pain; BPI average pain; opioid use; pain medication use; active fractures and pseudofractures; and 6-minute walking test distance.

The efficacy outcomes were as follows: serum phosphorus level (primary outcome), BPI worst pain, WOMAC stiffness, and WOMAC physical function (key secondary outcomes); and WOMAC pain, WOMAC total score, BPI average pain, BPI pain interference, BPI worst fatigue, BPI global score, patient global impression (PGI), and 6-minute walking distance.

In the overall cohort, at 24 weeks, in comparison with patients who received placebo, patients who received burosumab had favorable responses with respect to serum phosphorus level, WOMAC stiffness (P =. 012),WOMAC physical function (P = .048), and BPI worst pain (P = .092, not significant), as well as significant improvements in WOMAC total score and the 6-minute walk test. There were nonsignificant improvements in WOMAC pain and BPI average pain.

In the subgroup analysis, burosumab was superior to placebo for the primary outcome (serum phosphorus) in all subgroups. It was also superior to placebo for the key secondary outcomes (worst pain, stiffness, and physical function) across all subgroups except for patients from Asia (18 patients) and non-White patients (26).

The study was funded by Kyowa Kirin in partnership with Ultragenyx. Brandi receives consultancy and speaker fees as well as research grants from Kyowa Kirin and other pharmaceutical companies. Munns has received research funding from Kyowa Kirin.

The American Society of Bone and Mineral Research (ASBMR) 2020 Annual Meeting Virtual Event: Presented September 12, 2020.

For more diabetes and endocrinology news, follow us on Twitter and Facebook.

See original here:
Burosumab Is a 'Game Changer,' Effective in All Subgroups of XLH - Medscape

Recommendation and review posted by Bethany Smith

Spider-Man might not be a superhero typically known for his sidekicks, but he's definitely had some over the years. And these deserve a comeback.

It took Spider-Man a long time to finally relent and join a superhero team. Even then, it took the combined effort of Captain America and Iron Man to convince him. Before this, he had only been in the Avengers for a paltry four issues and had flirtations with the Defenders and the Fantastic Four. Even his Avengers membership had been as a reserve member.

RELATED: The Top Ten Spiderman And Deadpool Team Ups, Ranked

That does not mean the wall-crawler was exclusively a solo act. In fact, the long-running Marvel Team-Up featured Spider-Man in almost every issue of its thirteen-year run. Spider-Man was not averse to working with others, even if he did annoy most of his partners with his awkward gags. In fact, Spider-Man has nurtured and partnered with a lot of othercharacters in his time. From teenage runaways to reformed criminals, the web-slinger has had his fair share of sidekicks.

Robert Farrell has turned up on both sides of the law in his brief appearances. As well as being an adversary and sidekick of Spider-Man, he has also assisted the Avengers and worked undercover for S.H.I.E.L.D. As a child, realizing that the odds were stacked against him as a poor, black youth from the slums, he developed a rocket-powered skateboard. He used this to commit minor robberies to pay rent and bills for his mother.

After a stint on Ryker's Island, he reformed and began to assist Spider-Man. His cool, eighties look is very current. With his background that touches on themes inherent in the BLM movement, the world needs a new Rocket Racer story.

In her short stint in comics, Jackpot has developed quite a backstory. She began as an employee at Oscorp and was exposed to experimental gene therapy. This put her in a coma for four months, after which she awoke, gave birth, and realized she had developed super strength.

She was only a superhero briefly beforequitting to raise her daughter. In a very modern twist, she then sold her identity and brand. The new Jackpot teamed up with Spider-Man until her death when the outfit returned to its original occupant. The single mother superhero narrative has been approached in comics recently, but fans would be impressed to see a story involving a working superhero motherwho doesn't have a big team behind her.

Cloak and Dagger are two of the most recognizable of Spider-Man's sidekicks. They are so iconic, they even got their own television series. Since their debut in 1982, Tyrone and Tandy have been members of the Runaways, X-Men, and also fought alongside Captain America in the Civil War. They have even fought against heavyweights such as Doctor Doom and the Beyonder.

Fans adore Cloak and Dagger most when they are fighting street-level villains alongside Spider-Man. They were last seen guarding Hong Kong against the influence of Mr. Negative. Fans eagerly await their return home to New York.

Puma is a very complex ally to Spider-Man, and deserves to be more of a partner to Spidey than a sidekick. He is of Native American descent, and fiercely loyal to his heritage. Though a man of morals and good standing, he has also clashed with the web-slinger on some occasions.

RELATED: 5 Spiderman Villain Who Are Actually Sympathetic (& 5 Who Are Pure Evil)

His powers are a mix of martial arts training, technology, and Native American mysticism. As a successful businessman, it is surprising that his company, Fireheart Enterprises,never made deals with Parker industries. In a world polarized between the values of tradition and technology, fans would delight in a renewed version of the Puma.

Silver Sable has everything. She is a businesswoman, bounty hunter, a princess, and the owner of an international company. Despite lacking any actual super powers, she has access to a wealth of technology and is a fierce martial artist.

While not forgotten, Silver Sable is longoverdue a permanent comeback in the world of the wall-crawler. Her antagonistic nature and single-mindedness could either be a blessing or curse for Spider-Man. The idea of her as a private security consultant, as explored in the recent Spider-Man videogame, could see her tip the wall crawlers world upside down.

Cardiac's last appearance was during the Superior Spider-Man era when Doctor Octopus was inhabiting the body of Peter Parker. Despite friction, they decided they would still work together on medical research projects in the future. In fact, Cardiac even made Otto Octavius feel guilty about his past schemes, which is just the kind of character Cardiac is.

Elias Wirtham is a physician and owner of a biomedical research company who became Cardiac to right the wrongs ofgreedy pharmaceutical companies after the death of his brother. He is a medical Robin Hood, robbing drugs and equipment for those in need. While this can get him into trouble, his intent is always noble and he has partnered Spider-Man on many occasions.

Though he partnered with Spider-Man during the '90s, Nightwatch was anything but a good guy. In fact, in a bid to erase his former existence from history, he condemned a whole town to genocide. His motivation to be a hero was founded on the premise that they had the best retirement plans.

Nightwatch was last seen in the pages of She-Hulk, who brought him to justice using the law. Now atoning for his crimes in jail, a return from Nightwatch would finally allow him to make amends and reconcile his past sins. Who would be better equipped to help him do that than Spider-Man?

Of all the sidekicks that Spider-Man has had in his tenure, the most memorable come from a kooky TV series. Spider-Man and his Amazing Friends might not make much sense in terms of Spidey's comic book canon, but in the early '80s, this team-up cartoon was huge.

RELATED: Spider-Man: Ten New Characters Introduced During The Clone Saga

The team formed in episode one, movinginto Aunt May's apartment with a small dog and deciding to fight crime. For a modern update, the backstory may need reworking. They did have a brief reunion inanIceman mini-series.There's no doubt that fans would relish the chance to read a retro Amazing Friends comic in the vein of X-Men '92.

The White Tiger belongs to a legacy and has been a moniker adopted by five different heroes in the history of Marvel. The first White Tiger, Hector Ayala, was the hero most affiliated with Spider-Man. Hector carried a jade amulet that would let him transform into a White Tiger. He teamed up with Spider-Man many times in the'70s until he was accused of a crime he did not commit.

Despite the best efforts of his lawyer, Matt Murdock (Daredevil), he was found guilty and later assassinated. Ava Ayala, his younger sister, was the most recent to take uphis mantle of White Tiger. Whether she still has the White Tiger amulet or another has taken up the moniker remains to be seen.

Solo is a work for hire mercenary, similar in his outlook and abilities to The Punisher. He will use lethal means to get what he wants. Though this often brings him into conflict with the web-slinger, it has also meant that they have worked side by side on many occasions.

Solo's adventures have since taken him to some wild and wonderful situations. He has worked for Deadpoolas one of the "mercs for money"and even with S.H.I.E.L.D. in the past, though he is always best when trying to tow the line alongside Spider-Man.

NEXT: Spider-Man: The 10 Worst Things Black Cat Has Ever Done

Next Iron Fist Vs. Elektra: Who Would Win?

Carl Jackson is a typical English gentleman currently residing in Eastern Europe. He lives with his two cats, wife, and Neo Geo arcade machine. He is an avid retro gamer, collector of the eighties toy line M.A.S.K. and enjoys getting new ink on his Marvel vs Capcom sleeve.

See the article here:
10 Forgotten Spiderman Sidekicks They Need To Bring Back | CBR - CBR - Comic Book Resources

Recommendation and review posted by Bethany Smith

Provided by the Pennsylvania Department of Health:

Secretary of Health Dr. Rachel Levine today reminded Pennsylvanians of the seriousness of sickle cell disease and the importance of getting tested for it. Sickle cell disease is the most common inherited blood disease.

We want people to get tested for sickle cell disease if they believe they could be a carrier of it, Levine said. We inherit traits from our parents like eye and hair color, but they also pass along internal traits like blood type and sickle cell conditions. It is important to be tested to confirm if you have sickle cell disease, so that treatment for the disease can be started right away to further protect yourself and your family.

Sickle cell disease is an inherited blood disease where an individuals red blood cells take a crescent or sickle shape. This change in shape can create blockages that prevent blood from reaching parts of the body. As a result, people with sickle cell complications can experience anemia, gallstones, stroke, chronic pain, organ damage and even premature death.

According to the Centers for Disease Control and Prevention (CDC), sickle cell disease affects approximately 100,000 Americans. This disease has a greater influence on African American and Hispanic populations but is also found among many other races and ethnicities.

Sickle cell disease is one of the 10 mandatory diseasesscreened for newborns. These screenings are conducted with the goal of eliminating or reducing death, disease and disability in newborn children. In addition, sickle cell disease can be diagnosed before birth to provide an early diagnosis and find treatment.

Treatment can help those with sickle cell disease live well and be healthy, but there is ultimately no cure for sickle cell disease. Treatment requires:

Finding good medical care and getting regular checkups;

Staying up to date on vaccinations and washing hands frequently to prevent infections;

Learning healthy habits;

Looking into clinical studies; and

Finding support and assistance.

Studies have shown that donated bone marrow or stem cell transplants have helped cure sickle cell disease in children with severe cases of the disease. This means that the healthy donated bone marrow or stem cell transplant replaces an individuals bone marrow that is not working properly. Bone marrow or stem cell transplants can be risky and for the donation to work the individual would need to be a close match like a brother or sister.

The Wolf administration has developed aprescribing guideline for the treatment of acute and chronic pain in patients with sickle cell diseaseto assist physicians treating patients with the disease. The guideline provides best practices to treat acute painful crises that occur with sickle cell disease patients as well as best practices for chronic pain care. The sickle cell disease guideline addresses the specific needs of that patient population. This can help prevent the misapplication of recommendations to populations that are outside the scope of other prescribing guidelines, including patients experiencing acute sickle cell crises. It is especially important to have resources specifically for the treatment of sickle cell disease patients as this patient population often experiences racial disparities and stigma.

Report a correction via email | Editorial standards and policies

View post:
PA Health Secretary: Sickle Cell Disease Treatment Hinges On Getting Testing - LevittownNow.com

Recommendation and review posted by Bethany Smith

Transparency Market Research (TMR)has published a new report titled, Alpha mannosidosis Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20192027. According to the report, the globalalpha mannosidosis marketwas valued atUS$ 7.6 Mnin2018and is projected to expand at a CAGR of9.9%from2019to2027.

Request Brochure for Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2501

Overview

Patent-cliff To Drive Rare Disease Market to Drive Market

Request for Analysis of COVID19 Impact on Alpha mannosidosis Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=2501

Bone Marrow Transplant Segment to Dominate Market

Hospitals End-user segment to be Highly Lucrative Segment

Buy Alpha mannosidosis Market Report https://www.transparencymarketresearch.com/checkout.php?rep_id=2501&ltype=S

Competitive Landscape

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

Read this article:
Alpha mannosidosis Market projected to expand at a CAGR of 9.9% from 2019 to 2027 - The Daily Chronicle

Recommendation and review posted by Bethany Smith

Since late June, life has changed for Rylee Schroeder and her parents, Megan and Levi Schroeder.

It was then the Neosho High School senior sought help for extreme fatigue, shortness of breath, nosebleeds and more. The symptoms, combined with a previously diagnosed issue with low platelets, led Rylees pediatrician to run a series of lab tests.

The news sent the family first to Freeman Hospital West in Joplin, and then Childrens Mercy Hospital in Kansas City.

Doctors discovered Rylees low hemoglobin, platelets and white blood counts were caused by myelodysplastic syndrome. Additional testing revealed the teen has an extremely rare congenital disorder called Shwachman-Diamond syndrome and a TP53 gene mutation that led to the MDS.

Megan said her daughter is only the 36th patient known to have this combination of illnesses, which have progressed to bone marrow failure.

On Friday, Rylee received a stem cell bone marrow transplant at Childrens Mercy in Kansas City, thanks to a donation from her 12-year-old brother Colin.

Megan said her son was a 12/12 match for Rylee. Typically, doctors look for a 10/10 match, or a 5/5 match with a parent. The Be a Match Donor Registry located four 10/10 matches, two donors in the United States and two international donors.

If everything goes well with the transplant, doctors hope to see Colins stem cells begin to take hold in Rylees body between Day 14 to Day 21, post transplant.

Relying on faith

Through everything, Rylee and her family are relying on their faith, as well as support from friends at Racine Christian Church and within the community of Neosho, to get them through the tough days.

We are lucky to have a great church and thankful Sunday serves are online on Facebook, Megan said. We may not be there, but we still feel a part of it, and they are always ready to lift us up.

Many times, Ive thought Im not strong enough to do this, but Im reminded that I am. We are so tired and weary but (God) has us.

Megan said shes used to being the one to offer help through giving and volunteering. Now their family is on the other side, leaning on the support of others.

Our faith means everything to us, Megan said. Without it, we wouldnt be doing as well as we are. Its hard enough as it is. If you dont have something to believe in with your whole heart to guide you and lean on, you would just be lost. It would be overwhelming to take it on yourself.

More about Rylee

Rylee, who turned 17 shortly after her diagnosis, is active in the NHS show choir, choir, Key Club and FCA.

A member of the Racine Christian Church youth leadership team, she was also slated to go to Ireland this summer pre-pandemic with the churchs mission team.

This past Thursday, Rylee was highlighted at the NHS volleyball game for childhood cancer awareness month. On Friday, she was recognized at the home football game.

Members of her show choir helped start a Go Fund Me account earlier this summer to help the family with travel expenses to and from Kansas City. Her youth minister has since created another one to help with the coming months.

Megan said the family always helps at Solomons Dance Studio recitals because the owner, Charity, uses the lessons to teach children to love dance and to love others as well as themselves.

Rylee was able to to attend the recital to watch her sister Erin dance. On the last day of the recital, Charity asked the entire family to come forward, offering prayers over the entire situation.

Rylees small group from the church, which meets on Wednesday evenings, livechats with her, allowing the teen to continue to be part of the discussions.

Before Rylee was admitted to begin the chemo needed prior to the transplant, she asked to rededicate her life to Christ. Megan said she wanted to feel his strength renewed as she went into the fight.

Our close friends all stayed behind after church that Sunday, even though it was last minute, to be witness to her baptism, Megan said. They are some of our strongest supporters. We would be lost without them.

Megan said those friends, steeped in faith, give her strength to sit at the hospital, holding Rylees hand.

I can reach out to any of them to start praying with me to help make me feel stronger when I feel I am failing her, Megan said. I know Gods got this. He is strong all the time even when we can not be strong.

Biblical baubles

Many of Rylee Schroeders friends are wearing a Rally behind Rylee bracelet featuring Isaiah 41:10: So do not fear, for I am with you; do not be dismayed, for I am your God. I will strengthen you and help you; I will uphold you with my righteous right hand.

A family friend made them to distribute to members of the community. A limited number remain. Information about the bracelets, and Rylees journey, may be found on a Facebook page, Rally Behind Rylee.

Here is the original post:
Faith for the fight: Neosho teen deals with rare combination of illnesses - Joplin Globe

Recommendation and review posted by Bethany Smith

Transparency Market Research (TMR) has published a new report titled, Cord Blood Banking Services Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20192027. According to the report, the globalcord blood banking services marketwas valued atUS$ 25.8 Mnin2018and is projected to expand at a CAGR of10.9%from2019to2027.

Overview

Request a PDF Brochure https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1741

High Incidence of genetic disorders and rise in hematopoietic stem cell transplantation rates to Drive Market

Private Cord Blood Bank Segment to Dominate Market

Request for Analysis of COVID19 Impact on Cord Blood Banking Services Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1741

North America to Dominate Global Market

Competitive Landscape

Purchase Cord Blood Banking Services Market Report https://www.transparencymarketresearch.com/checkout.php?rep_id=1741&ltype=S

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants, uses proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website:https://www.transparencymarketresearch.com/

Read the original post:
Cord Blood Banking Services Market Estimated to Expand at a Robust CAGR by 2025 - Verdant News

Recommendation and review posted by Bethany Smith

The Stem Cell Banking market is expected to grow from USD X.X million in 2020 to USD X.X million by 2026, at a CAGR of X.X% during the forecast period. The global Stem Cell Banking market report is a comprehensive research that focuses on the overall consumption structure, development trends, sales models and sales of top countries in the global Stem Cell Banking market. The report focuses on well-known providers in the global Stem Cell Banking industry, market segments, competition, and the macro environment.

Under COVID-19 Outbreak, how the Stem Cell Banking Industry will develop is also analyzed in detail in Chapter 1.7 of the report., In Chapter 2.4, we analyzed industry trends in the context of COVID-19., In Chapter 3.5, we analyzed the impact of COVID-19 on the product industry chain based on the upstream and downstream markets., In Chapters 6 to 10 of the report, we analyze the impact of COVID-19 on various regions and major countries., In chapter 13.5, the impact of COVID-19 on the future development of the industry is pointed out.

A holistic study of the market is made by considering a variety of factors, from demographics conditions and business cycles in a particular country to market-specific microeconomic impacts. The study found the shift in market paradigms in terms of regional competitive advantage and the competitive landscape of major players.

Download PDF Sample of Stem Cell Banking Market report @ https://www.arcognizance.com/enquiry-sample/1315141

Key players in the global Stem Cell Banking market covered in Chapter 4:, Boyalife, StemCyte, Crioestaminal, Esperite, Americord, Cryo-cell, PBKM FamiCord, Beikebiotech, PacifiCord, RMS Regrow, Stemade Biotech, Krio, CCBC, Cordlife Group, Cellsafe Biotech Group, Vcanbio, Familycord, ViaCord, Cells4life, LifeCell, CBR, Cryo Stemcell

In Chapter 11 and 13.3, on the basis of types, the Stem Cell Banking market from 2015 to 2026 is primarily split into:, Placental Stem Cells (PSCs), Human Embryo-derived Stem Cells (HESCs), Bone Marrow-derived Stem Cells (BMSCs), Adipose Tissue-derived Stem Cells (ADSCs), Dental Pulp-derived Stem Cells (DPSCs), Other Stem Cell Sources

In Chapter 12 and 13.4, on the basis of applications, the Stem Cell Banking market from 2015 to 2026 covers:, Personalized Banking Applications, Clinical Applications, Hematopoietic Disorders, Autoimmune Disorders, Other Diseases, Research Applications, Disease Treatment Studies, Life Science Research, Drug Discovery

Check Discount

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:, North America (Covered in Chapter 6 and 13), United States, Canada, Mexico, Europe (Covered in Chapter 7 and 13), Germany, UK, France, Italy, Spain, Russia, Others, Asia-Pacific (Covered in Chapter 8 and 13), China, Japan, South Korea, Australia, India, Southeast Asia, Others, Middle East and Africa (Covered in Chapter 9 and 13), Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Others, South America (Covered in Chapter 10 and 13), Brazil, Argentina, Columbia, Chile, Others

Years considered for this report:, Historical Years: 2015-2019, Base Year: 2019, Estimated Year: 2020, Forecast Period: 2020-2026

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Stem Cell Banking Market

Chapter Four: Players Profiles

Chapter Five: Global Stem Cell Banking Market Analysis by Regions

[emailprotected] https://www.arcognizance.com/purchase/1315141

Chapter Six: North America Stem Cell Banking Market Analysis by Countries

Chapter Seven: Europe Stem Cell Banking Market Analysis by Countries

Chapter Eight: Asia-Pacific Stem Cell Banking Market Analysis by Countries

Chapter Nine: Middle East and Africa Stem Cell Banking Market Analysis by Countries

Chapter Ten: South America Stem Cell Banking Market Analysis by Countries

Chapter Eleven: Global Stem Cell Banking Market Segment by Types

Chapter Twelve: Global Stem Cell Banking Market Segment by Applications12.1 Global Stem Cell Banking Sales, Revenue and Market Share by Applications (2015-2020)12.1.1 Global Stem Cell Banking Sales and Market Share by Applications (2015-2020)12.1.2 Global Stem Cell Banking Revenue and Market Share by Applications (2015-2020)12.2 Personalized Banking Applications Sales, Revenue and Growth Rate (2015-2020)12.3 Clinical Applications Sales, Revenue and Growth Rate (2015-2020)12.4 Hematopoietic Disorders Sales, Revenue and Growth Rate (2015-2020)12.5 Autoimmune Disorders Sales, Revenue and Growth Rate (2015-2020)12.6 Other Diseases Sales, Revenue and Growth Rate (2015-2020)12.7 Research Applications Sales, Revenue and Growth Rate (2015-2020)12.8 Disease Treatment Studies Sales, Revenue and Growth Rate (2015-2020)12.9 Life Science Research Sales, Revenue and Growth Rate (2015-2020)12.10 Drug Discovery Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Stem Cell Banking Market Forecast by Regions (2020-2026) continue

List of tablesList of Tables and FiguresTable Global Stem Cell Banking Market Size Growth Rate by Type (2020-2026)Figure Global Stem Cell Banking Market Share by Type in 2019 & 2026Figure Placental Stem Cells (PSCs) FeaturesFigure Human Embryo-derived Stem Cells (HESCs) FeaturesFigure Bone Marrow-derived Stem Cells (BMSCs) FeaturesFigure Adipose Tissue-derived Stem Cells (ADSCs) FeaturesFigure Dental Pulp-derived Stem Cells (DPSCs) FeaturesFigure Other Stem Cell Sources FeaturesTable Global Stem Cell Banking Market Size Growth by Application (2020-2026)Figure Global Stem Cell Banking Market Share by Application in 2019 & 2026Figure Personalized Banking Applications DescriptionFigure Clinical Applications DescriptionFigure Hematopoietic Disorders DescriptionFigure Autoimmune Disorders DescriptionFigure Other Diseases DescriptionFigure Research Applications DescriptionFigure Disease Treatment Studies DescriptionFigure Life Science Research DescriptionFigure Drug Discovery DescriptionFigure Global COVID-19 Status OverviewTable Influence of COVID-19 Outbreak on Stem Cell Banking Industry DevelopmentTable SWOT AnalysisFigure Porters Five Forces AnalysisFigure Global Stem Cell Banking Market Size and Growth Rate 2015-2026Table Industry NewsTable Industry PoliciesFigure Value Chain Status of Stem Cell BankingFigure Production Process of Stem Cell BankingFigure Manufacturing Cost Structure of Stem Cell BankingFigure Major Company Analysis (by Business Distribution Base, by Product Type)Table Downstream Major Customer Analysis (by Region)Table Boyalife ProfileTable Boyalife Production, Value, Price, Gross Margin 2015-2020Table StemCyte ProfileTable StemCyte Production, Value, Price, Gross Margin 2015-2020Table Crioestaminal ProfileTable Crioestaminal Production, Value, Price, Gross Margin 2015-2020Table Esperite ProfileTable Esperite Production, Value, Price, Gross Margin 2015-2020Table Americord ProfileTable Americord Production, Value, Price, Gross Margin 2015-2020Table Cryo-cell ProfileTable Cryo-cell Production, Value, Price, Gross Margin 2015-2020Table PBKM FamiCord ProfileTable PBKM FamiCord Production, Value, Price, Gross Margin 2015-2020Table Beikebiotech ProfileTable Beikebiotech Production, Value, Price, Gross Margin 2015-2020Table PacifiCord ProfileTable PacifiCord Production, Value, Price, Gross Margin 2015-2020Table RMS Regrow ProfileTable RMS Regrow Production, Value, Price, Gross Margin 2015-2020Table Stemade Biotech ProfileTable Stemade Biotech Production, Value, Price, Gross Margin 2015-2020Table Krio ProfileTable Krio Production, Value, Price, Gross Margin 2015-2020Table CCBC ProfileTable CCBC Production, Value, Price, Gross Margin 2015-2020Table Cordlife Group ProfileTable Cordlife Group Production, Value, Price, Gross Margin 2015-2020Table Cellsafe Biotech Group ProfileTable Cellsafe Biotech Group Production, Value, Price, Gross Margin 2015-2020Table Vcanbio ProfileTable Vcanbio Production, Value, Price, Gross Margin 2015-2020Table Familycord ProfileTable Familycord Production, Value, Price, Gross Margin 2015-2020Table ViaCord ProfileTable ViaCord Production, Value, Price, Gross Margin 2015-2020Table Cells4life ProfileTable Cells4life Production, Value, Price, Gross Margin 2015-2020Table LifeCell ProfileTable LifeCell Production, Value, Price, Gross Margin 2015-2020Table CBR ProfileTable CBR Production, Value, Price, Gross Margin 2015-2020Table Cryo Stemcell ProfileTable Cryo Stemcell Production, Value, Price, Gross Margin 2015-2020Figure Global Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Global Stem Cell Banking Revenue ($) and Growth (2015-2020)Table Global Stem Cell Banking Sales by Regions (2015-2020)Table Global Stem Cell Banking Sales Market Share by Regions (2015-2020)Table Global Stem Cell Banking Revenue ($) by Regions (2015-2020)Table Global Stem Cell Banking Revenue Market Share by Regions (2015-2020)Table Global Stem Cell Banking Revenue Market Share by Regions in 2015Table Global Stem Cell Banking Revenue Market Share by Regions in 2019Figure North America Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Europe Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Asia-Pacific Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Middle East and Africa Stem Cell Banking Sales and Growth Rate (2015-2020)Figure South America Stem Cell Banking Sales and Growth Rate (2015-2020)Figure North America Stem Cell Banking Revenue ($) and Growth (2015-2020)Table North America Stem Cell Banking Sales by Countries (2015-2020)Table North America Stem Cell Banking Sales Market Share by Countries (2015-2020)Figure North America Stem Cell Banking Sales Market Share by Countries in 2015Figure North America Stem Cell Banking Sales Market Share by Countries in 2019Table North America Stem Cell Banking Revenue ($) by Countries (2015-2020)Table North America Stem Cell Banking Revenue Market Share by Countries (2015-2020)Figure North America Stem Cell Banking Revenue Market Share by Countries in 2015Figure North America Stem Cell Banking Revenue Market Share by Countries in 2019Figure United States Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Canada Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Mexico Stem Cell Banking Sales and Growth (2015-2020)Figure Europe Stem Cell Banking Revenue ($) Growth (2015-2020)Table Europe Stem Cell Banking Sales by Countries (2015-2020)Table Europe Stem Cell Banking Sales Market Share by Countries (2015-2020)Figure Europe Stem Cell Banking Sales Market Share by Countries in 2015Figure Europe Stem Cell Banking Sales Market Share by Countries in 2019Table Europe Stem Cell Banking Revenue ($) by Countries (2015-2020)Table Europe Stem Cell Banking Revenue Market Share by Countries (2015-2020)Figure Europe Stem Cell Banking Revenue Market Share by Countries in 2015Figure Europe Stem Cell Banking Revenue Market Share by Countries in 2019Figure Germany Stem Cell Banking Sales and Growth Rate (2015-2020)Figure UK Stem Cell Banking Sales and Growth Rate (2015-2020)Figure France Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Italy Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Spain Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Russia Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Asia-Pacific Stem Cell Banking Revenue ($) and Growth (2015-2020)Table Asia-Pacific Stem Cell Banking Sales by Countries (2015-2020)Table Asia-Pacific Stem Cell Banking Sales Market Share by Countries (2015-2020)Figure Asia-Pacific Stem Cell Banking Sales Market Share by Countries in 2015Figure Asia-Pacific Stem Cell Banking Sales Market Share by Countries in 2019Table Asia-Pacific Stem Cell Banking Revenue ($) by Countries (2015-2020)Table Asia-Pacific Stem Cell Banking Revenue Market Share by Countries (2015-2020)Figure Asia-Pacific Stem Cell Banking Revenue Market Share by Countries in 2015Figure Asia-Pacific Stem Cell Banking Revenue Market Share by Countries in 2019Figure China Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Japan Stem Cell Banking Sales and Growth Rate (2015-2020)Figure South Korea Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Australia Stem Cell Banking Sales and Growth Rate (2015-2020)Figure India Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Southeast Asia Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Middle East and Africa Stem Cell Banking Revenue ($) and Growth (2015-2020)continue

If you have any special requirements, please let us know and we will offer you the report as you want.

Trending Report URLs:

https://www.marketwatch.com/press-release/in-vitro-cancer-diagnostics-market-size-rising-impact-of-covid-19-share-trends-growth-opportunities-and-top-key-players-2024-2020-07-31

https://www.marketwatch.com/press-release/2020-instant-cameras-market-size-rising-impact-of-covid-19-competitive-insights-production-and-demand-to-2024-2020-07-31

About Us:Analytical Research Cognizance (ARC)is a trusted hub for research reports that critically renders accurate and statistical data for your business growth. Our extensive database of examined market reports places us amongst the best industry report firms. Our professionally equipped team further strengthens ARCs potential.ARC works with the mission of creating a platform where marketers can have access to informative, latest and well researched reports. To achieve this aim our experts tactically scrutinize every report that comes under their eye.

Contact Us:Ranjeet DengaleDirector SalesAnalytical Research Cognizance+1 (646) 403-4695, +91 90967 44448Email: [emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

See original here:
COVID-19 Outbreak- Global Stem Cell Banking Market 2020 analysis with Key Players, Applications, Trends and Forecasts by 2026 - Crypto Daily

Recommendation and review posted by Bethany Smith

INREBIC provides new, once-daily oral option for patients affectedby rare bone marrow cancer

MONTREAL, Sept. 21, 2020 /CNW/ - Bristol Myers Squibb Canada (BMS) announced today that Health Canada has approved INREBIC (fedratinib), a new once-daily oral medication used to treat adults with an enlarged spleen and associated symptoms caused by intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.1

INREBICis the first new treatment for patients with myelofibrosis in nearly a decade to demonstrate a clinically meaningful reduction in spleen volume for patients in the approved population affected by this serious and rare bone marrow cancer.1 A new treatment provides Canadians living with myelofibrosis, and their caregivers, with more options to find a treatment that works for them.

Myelofibrosis is a serious and rare bone marrow disorder that disrupts the body's normal production of blood cells.2 Bone marrow is gradually replaced with fibrous scar tissue, which limits the ability of the bone marrow to make blood cells.2 Currently, there are an estimated 1,400 to 2,177 Canadians who are living with myelofibrosis.3

"The approval of INREBIC represents a milestone for the way healthcare practitioners treat this rare disorder, which can have debilitating symptoms," said Dr. Vikas Gupta, Director, The Elizabeth and Tony Comper MPN Program, Princess Margaret Cancer Centre, Toronto. "Canadians living with myelofibrosis now have a new treatment option that may be better suited to their needs and has shown promise for alleviating the symptom burden associated with myelofibrosis."

INREBIC is a janus kinase (JAK) inhibitor and is the first new treatment for patients with myelofibrosis in nearly a decade.1,4 JAK proteins send signals that tell the body to make more blood cells, but myelofibrosis makes it difficult for the bone marrow to create normal blood cells, which potentially moves blood cell production to the spleen.1 However, by blocking the activity of JAK proteins, INREBIC can reduce the size of the spleen and improve symptoms.

Story continues

"As part of our commitment to Canadians living with cancer, we are excited to provide INREBIC as a new treatment option for those impacted by myelofibrosis," said Al Reba, General Manager, Bristol Myers Squibb Canada. "We hope that the option of a once-daily oral treatment will have a positive and meaningful impact on Canadians living with the disease."

Health Canada's approval of INREBIC included findings from the JAKARTA and JAKARTA2 clinical trials. The JAKARTA study, a double-blind, randomized, placebo-controlled Phase 3 study, involved patients with intermediate-2 or high-risk myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis. The JAKARTA2 study, a multicenter, open-label, single-arm Phase 2 study,involved patients previously exposed to ruxolitinib with a diagnosis of intermediate-1 with symptoms, intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.

About MyelofibrosisMyelofibrosis is classified as a myeloproliferative neoplasm, a group of rare blood cancers that are derived from blood-forming stem cells.2Myelofibrosis can lead to anemia and thrombocytopenia, weakness, fatigue and enlargement of the spleen and liver, among other symptoms.2 In Canada, approximately 36 to 360 people will be diagnosed with myelofibrosis each year.3 Both men and women are affected, and while the disease can affect people of all ages, the median age at diagnosis is 69 years old.3

About JAKARTAJAKARTA was a double-blind, randomized, placebo-controlled Phase 3 study in patients with intermediate-2 or high-risk myelofibrosis (MF), post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis with splenomegaly and platelet count 50 x 109/L. A total of 289 patients were randomized to receive either INREBIC 500 mg (N=97), 400 mg (N=96), or placebo (N=96) once daily for at least 6 cycles. The median age was 65 years (range 27 to 86 years), 47% of patients were older than 65 years, and 59% were male. Sixty-four percent (64%) of patients had primary MF, 26% had post-polycythemia vera MF, and 10% had post-essential thrombocythemia MF. Fifty-two percent (52%) of patients had intermediate-2 risk, and 48% had high-risk disease. The median hemoglobin count at baseline was 10.2 g/dL. The median platelet count at baseline was 213.5 x 109/L; 16.3% of patients had a platelet count <100 x 109/L, and 83.7% of patients had a platelet count 100 x 109/L. Patients had a median palpable spleen length of 15 cm at baseline and a median spleen volume as measured by magnetic resonance imaging (MRI) or computed tomography (CT) of 2568 mL (range of 316 to 8244 mL) at baseline. (The median normal spleen volume is approximately 215 mL).1

The primary efficacy endpoint was the proportion of patients achieving a greater than or equal to 35% reduction from baseline in spleen volume at the End of Cycle 6 as measured by MRI or CT and confirmed 4 weeks later.1

One of the secondary endpoints was the proportion of patients with a 50% or greater reduction in Total Symptom Score (TSS) from baseline to the End of Cycle 6 as measured by the modified Myelofibrosis Symptoms Assessment Form (MFSAF) v2.0 diary.1

About JAKARTA2JAKARTA2 was a multicenter, open-label, single-arm Phase 2 study in patients previously exposed to ruxolitinib with a diagnosis of intermediate-1 with symptoms, intermediate-2 or high-risk myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis with splenomegaly and platelet count 50 x 109/L.1

A total of 97 patients were enrolled and treated with INREBIC400 mg once daily. The median age was 67 years (range 38 to 83 years) with 58% of patients older than 65 years and 55% were male. Fifty-five percent (55%) of patients had primary MF, 26% had post-polycythemia vera MF, and 19% had post-essential thrombocythemia MF. Sixteen percent (16%) of patients had intermediate-1 with symptoms, 49% had intermediate-2, and 35% had high-risk disease. The median hemoglobin count was 9.8 g/dL at baseline. The median platelet count was 147.0 x 109/L at baseline; 34.0% of patients had a platelet count <100 x 109/L, and 66.0% of patients had a platelet count 100 x 109/L. Patients had a median palpable spleen length of 18 cm at baseline and a median spleen volume as measured by magnetic resonance imaging (MRI) or computed tomography (CT) of 2893.5 mL (range of 737 to 7815 mL) at baseline.1

The median duration of prior exposure to ruxolitinib was 10.7 months (range 0.1 to 62.4 months). Seventy-one percent (71%) of patients had received doses of either 30 mg or 40 mg daily of ruxolitinib prior to study entry.1

The primary endpoint was the subject response rate, defined as the proportion of subjects who have a 35% reduction in volume of spleen size at the end of Cycle 6.1

One of the secondary endpoints was the proportion of patients with a 50% or greater reduction in Total Symptom Score (TSS) from baseline to the End of Cycle 6 as measured by the modified Myelofibrosis Symptoms Assessment Form (MFSAF) diary.1

About INREBICINREBIC (fedratinib) is indicated for the treatment of splenomegaly and/or disease related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been previously exposed to ruxolitinib.

About Bristol Myers Squibb Canada

Bristol Myers Squibb Canada Co. is an indirect wholly-owned subsidiary of Bristol Myers Squibb Company, a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb global operations, visitwww.bms.com. Bristol Myers Squibb Canada Co. delivers innovative medicines for serious diseases to Canadian patients in the areas of cardiovascular health, oncology, and immunoscience. Bristol Myers Squibb Canada Co. employs more than 300 people across the country. For more information, please visitwww.bmscanada.ca.

About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us atBMS.comor follow us on LinkedIn, Twitter, YouTube, Facebookand Instagram.

Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company.

References:

INREBICCanada Product Monograph. July 10, 2010.

Leukemia & Lymphoma Society of Canada. Myelofibrosis. Available at: https://www.llscanada.org/myeloproliferative-neoplasms/myelofibrosis. Accessed July 28, 2020.

Corinne S. Hodgson & Associates. Blood Cancer in Canada Facts & Stats 2016. Leukemia & Lymphoma Society of Canada 2016; 4-8.

Canadian MPN Group. Myelofibrosis. Available at: http://www.mpncanada.com/about-mpns/practitioner-reference/myelofibrosis/#treatment-options. Accessed July 28, 2020.

SOURCE Bristol Myers Squibb Canada Co.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2020/21/c8189.html

See the article here:
Health Canada Approves INREBIC (fedratinib), First New Treatment in Nearly a Decade for Patients Living with Myelofibrosis - Yahoo Finance

Recommendation and review posted by Bethany Smith

Castrating male piglets has always been quite a controversial topic for farmers and consumers alike, but more pressure is being applied these days by the latter to ban the practice.

It is common knowledge that the meat from uncastrated males can have a rather unpleasant smell or taste when it is cooked: this is known as boar taint. During a recent webinar facilitated by the group Innovative Approaches for Pork Production with Entire Males (IPEMA), a body supported by the EU to look at various methods to producing entire male pigs, a number of alternatives to the surgical castration of piglets were discussed.

Preparations for castration. Will the practice continue as it is? - Photo: Mark Pasveer

Castrated male pigs convert feed to meat less efficiently than entire males but the process of surgical castration without pain relief is painful to the animal. There is a growing consensus within Europe that this process should be discontinued favouring a different approach. In total, 3 different alternatives are available including surgical castration with pain relief, immunocastration and simply leaving the animals as entire males.

IPEMA classifies surgical castration with pain relief as an intermediate short term solution that is inefficient and adds costs. Focusing on the other 2 alternatives, IPEMA found that leaving the pigs uncastrated as entire males increased the aggressive behaviour of the animals and that they mounted their pen mates.

Also, there were issues with boar taint on the meat and other meat quality problems such as lower fat amounts, and being less tender.

During immunocastration, a vaccine is injected that inhibits steroid production by the testes. It is only when a second vaccination is administered, that there is any difference to the animals behaviour and a gradual improvement to meat quality.

There is a number of issues associated with immunocastration including stress during vaccination, and some concerns over meat quality depending on the timing of the second vaccination to the time of slaughter. The biggest challenge though, is that most markets in the European Union are reluctant to accept this as a husbandry process as they assume consumers are against it.

There was discussion as well about how breeding and genetics can be used as tools to reduce boar taint, improve the meat quality and reduce aggressive behaviour of entire male pigs. At the end of the day, whatever method is used going forward will be heavily influenced by consumer and market demands.

During the past 20 years, surgical castration of piglets has been strongly contested by animal welfare organisations. The discussions acknowledged that each of the alternatives has pros and cons but the biggest road blocks to consumer acceptance were boar taint for entire male production and consumer acceptance of immunocastration.

Dutch pig farmer Annechien ten Have-Mellema closed the webinar by recognising there is a lot of work to do on the topic of pig castration. She said: A lot of scientists are working on the alternatives for pig castration. It is a complex issue and it is very nice that there is a collaboration in this network between scientists and stakeholders in the supply chain.

She continued to say, We can see that Europe is moving to pig castration with anaesthesia, immuno vaccination, or towards entire males. We are all on a different stage but the process is irreversible. The work is not ready and has only started. Awareness and knowledge sharing is very important. The European Union also has a responsibility to facilitate this work.

Read the rest here:
Examining the alternatives to piglet castration - Pig Progress

Recommendation and review posted by Bethany Smith

by Nabaa Muhammad and Michael Z. Muhammad | The Final Call | @TheFinalCall

Emphatically no, Walt Boarderly, an entrepreneur and Philadelphia business owner, replied when asked if he would take the Covid-19 vaccine. Mr. Boaderly isnt anti-vaccine, saying he will take the flu shot. There is just too much uncertainty when it comes to this new vaccine, he said.

Blacks do not trust President Trumps Covid-19 vaccine push, and there is plenty of reason to be distrustful. Black people have been the victims of medical experiment, exploitation and abuses by their White enslavers and White doctors from the time the good ship Jesus hit Americas shores. These medical researchers have been like a pack of crazed dogs chasing their helpless prey.

In her comprehensive book Medical Apartheid, Harriett Washington details abuses committed against Blacks and how throughout the 19th century medical schools used Blacks in live surgical demonstrations.

In more recent times, she wrote, Blacks have been disproportionately enrolled in risky, nonbeneficial research in gynecology, oncology, surgery, pediatrics, infectious diseases, and genetics.

Medical Apartheid tells the story of slaves and Black freedmen used in hospitals for experiments without their knowledge or consent. Blacks have historically been victims of grave-robbing, unauthorized autopsies and dissections, Frankenstein-like behavior by White medical researchers.

The American Medical Womens Association sponsored a Sept. 19 Zoom conversation on Medical Apartheid as part of its Racism in Medicine Monthly Discussion.

Primary participants in the discussion were medical students and pre-med students.

The session opened with some basic questions, like whether doctors during slavery focused on the health of enslaved persons. Surprisingly many participants believed those doctors were concerned about slaves healththey werent. The doctors had a pact to inspect slaves to make sure they were fit for work, to determine their value given their ability to work and performed examinations for insurance companies before policies on slaves were issued to slave owners.

Dr. P. Oneeka Williams, a urologist based in Brighton, Mass., was one of two main presenters. She saluted Ms. Washington for her work and talked about the pervasive practice of using enslaved people for experiments.

She focused on Dr. James Marion Sims as the father of gynecology, lionized for his treatments for women. But, said Dr. Williams, These advances along with so many other physicians, really came on the backs of the violations and the atrocities and the disgusting treatment of Black bodies.

Born in 1813 in South Carolina, Dr. Simms underwent one and a half years of medical training, which he considered inadequate and started practicing on Alabama plantations. He experimented on enslaved Black children stricken by tetanus and enslaved Black women. In 1845, he used forceps, despite limited experience, to deliver a child from a slave girl. The baby died and the mother developed a vesicorectal fistula, a devastating condition involving the bladder and the rectum. It was a condition that women, Black and White, often suffered from. He acquired 11 slave women with the condition, housed them and started experimenting with surgical repair. The woman had no consent, no anesthesia and were put on display. The surgeries were painful, frequently broke down and required multiple surgeries with physicians coming to observe his procedures, said Dr. Williams, a Black woman. The enslaved womens piercing screams could be heard, she said.

Dr. Simms developed a procedure to treat the condition, practicing for three years on enslaved Black women. He started publishing articles about his dubious success in 1852 and began operating on White women. As abolitionists objected to using Blacks for medical experimentation, he started to hide the race of his test subjects. He later became president of the American Medical Association and opened the first hospital for women in New York City in 1875. His name is enshrined on buildings, hospitals and statues were erected in his honor.

In 2018, protests led to the removal of his statue in New Yorks Central Park. Officials relocated it to his gravesite in Brooklyn.

Biases and racism would not impact on the medical profession any differently than it impacts on any other categories in life, said Dr. Williams.

Race-based beliefs became seen as real science and are still perpetuated, she added.

Dr. Williams believes educating and raising awareness of medical students and professionals alongside elementary, high school and college students are important to help resolve the problem. She has seen instances today in which physicians have not valued Black lives, though it may not be conscious.

Medical Apartheid chronicles how in the 17th and 18th century enslaved Blacks were used for vaccine trials, smallpox in particular, without their consent and once the vaccines were effective, the cures were released into the general population, said Dr. Williams.

We have to look at history so that when people try to diminish the concerns of Black people about being potentially the unwitting participants of some type of trial that is about using us as guinea pigs that its not a kind of hearsay. Its not oh I think, Im guessing, she continued.

Here its factual information that supports why the skepticism exists and why there has to be a clear set of strategies about how do you really help Blacks to feel confident and reassured that they are not going to be used in a kind of experimentation process that has been done even in our contemporary times. This is not centuries ago, this is within recent history, 10, 20, 30 years, were still seeing situations where Blacks have been used as part of unconsenting experimental protocols to their detriment.

Even the infamous Tuskegee Experiment has aspects that are not generally talked about. In Medical Apartheid, the author reveals how the syphilis study, started in 1932, was based on the belief that racial differences and irresponsible Black behavior accounted for syphilis infections among poor Blacks. Most cases were actually due to disease transmission from mothers to children.

There was a profit motive in the study as the federal government hoped to come out with a lucrative vaccine and wanted to follow the 600 male patients until they died.

When the federal governments wickedness was uncovered, some documents were hidden from a panel that was supposed to look into the genocidal activity and the victims were eventually paid a pittance. In 1943, penicillin, a treatment for syphilis, was discovered but never given to study victims. In addition to the deaths of the men, at least 40 wives and almost 20 children were infected.

In 1965, the study was discovered and a leftist, social activist group tried to stop it, but was ignored. By 1969, 100 men had died from direct and indirect complications from syphilis. Peter Buxton, a Polish immigrant, working within the study called for ending it. In 1972, he shared the nefarious experiment with a friend, who was an AP reporter. Ted Kennedy held hearings, an investigation was opened, but a historian was never involved and a panel was formed to look into the study. The panel was given less than one year to do its work, some documents were deliberately hidden, the panel chair forced a softening of the language of the initial report and submitted it with a cover letter abstaining from agreement with the report.

Tapes of interviews with every victim were kept but destroyed, and in 1995 a doctor determined the studys chief purpose was to create a reliable vaccine and the results of the study were used to create advanced tests for syphilis and vaccines that were marketed globally.

The original U.S. contract with the Alabama Dept. of Health stipulated that the U.S. government owns any invention arising from the Tuskegee Syphilis Study, and so, the U.S. government profited tremendously off the backs of these men and their families and continued to do so, said the moderator for the online session. The CDC also soft pedals the Tuskegee Syphilis Study, though President Clinton apologized for it, she added.

If you look at themes throughout the book, this is all economically driven, commented Dr. Williams. The very agencies that are supposed to be committed to protect the population, to protect the people, the American government, when you look at what was really the motivation for this study.

Even today we are seeing what we are seeing with covid and misinformation, deception, parties that are changing the narrative, changing information, changing things that impact our peoples lives, she said. Things like not testing asymptomatic people have far-reaching effects into the health of the nation, Dr. Williams observed.

Youre exposing people to a potential deadly pathogen, she continued. But who are the people who are disproportionately suffering from that virus? All of these threads when you look at how interwoven the government agencies have been in the deception, in the abuse of Black and Brown bodies, its really very, very disconcerting, said Dr. Williams.

Black only medicine?

Dr. Vanessa Al Rashida, who practices medicine in New Mexico, presented information about the continued use of race as a basis for research based on a chapter in Medical Apartheid.

The public health field has contributed to misinformation going back to slavery, said Dr. Al Rashida. Early U.S. Census studies found free Blacks suffered more from alcoholism and died because of recklessness, she said. The theory was Whites needed to shepherd Black people, the physician added.

In 2005, a drug that the Food and Drug Administration initially denied for wide use was approved for use only in Black Americans with heart failure, she said. The drug was Bidil.

In the 1980s, surveys had found heart failure was twice as common in older Blacks than Caucasians, which is not the case today, she said.

But Blacks dying more often led the company NitroMed to postulate a genetic cause of the disease disparity. FDA approved research for the drug. Clyde Yancey, a Black cardiologist, and others objected to the premise of race-based differences as opposed to differences based on environment and lifestyle. The NitroMed approach ignored these things but a Black cardiologists group approved the study.

Most diseases Blacks suffer are driven by environment, not any inherent difference based on genetics and race, said Dr. Al Rashida.

The African American Heart Failure Trials in 2003 was composed of Blacks only, one group with approved heart medications put against another group of Black Americans using heart medications and Bidil, she explained.

She questioned the methodology of the study, which showed some Bidil benefit in curbing deaths, and FDA approved the drug which is still used today.

The study made me sick for a while, said Dr. Al Rashida.

A non-genetic disease of heart failure, which other studies have shown is often due to high blood pressure caused by environmental factors in Black Americans, is being treated with genetic treatments, she said. That concerns her. Research has shown little genetic difference between people based on race, said Dr. Al Rashida, who read Medical Apartheid in medical school. It was given to her as a gift from a family friend.

The Nitro-Med study would have had more weight if it compared Black Americans to Caucasians, she said. But, it only compared Black Americans and the reason for that was money, she said.

It was not economically feasible for the company to add in Caucasians with African Americans to be compared in the study, said Dr. Al Rashida.

Its also kind of scary to me that future studies are being based on this whole precipice that race is playing a part in diseases that we are seeing in the country. Whereas thats not the case at all. Its environment and its also lifestyle behaviors too that have been rooted back into slavery.

That includes how Black people eat, added Dr. Al Rashida.

I try to be very optimistic and I want to see better for our country, but at the same time, its very scaryespecially with the current leadership that we have in certain institutions. Its going to be a very difficult hill to climb essentially, she said.

If research determines that illness or disorders are based on racial differences, not environment, it is easier to dismiss the need to make changes in society and argue the conditions or illnesses are inevitable.

Prisons, hospitals and the devils playground for reckless research

There are other concerns about vaccines and negative impacts on Blacks. Since 2014, controversy has brewed over a Centers for Disease researcher who charged the agency with hiding research results linking an experimental measles vaccines with increased Black male children developing autism. Dr. William Thompson, who made the charges, has called for an opportunity to testify before Congress. Though CDC denies his charge, there has been no congressional hearing.

Ms. Washington has written about a 1970 Johns Hopkins Free Child Care program for more than 7,000 young boys, 95 percent from underprivileged Negro familieswho used as guinea pigs in a three-year experiment that could have branded them as latent criminals for life. Funded by the National Institutes of Health, the project extracted blood samples, ostensibly to test for anemia and other medical problems. She wrote that testing was done without parental knowledge or consent.

In a piece published in the Baltimore Sun, Ms. Washington wrote, In 1962, Dr. Chester M. Southam of the Sloan-Kettering Institute injected at least 396 inmates at Ohio State Prisonalmost half of them blackwith live humancancercells.

According to Allan Hornblum, author of Acres of Skin: Human Experiments at Holmesburg Prison, Holmesburg Prison became one of Americas largest, nontherapeutic, human research factories. The Pennsylvania prison was about 85 percent Black, and there were very few high school graduates, he wrote.

Dr. Albert Kligman, Ph.D. and M.D., University of Pennsylvania, began dermatology research before 1951 when he visited the prison, said the book author.

Dr. Klingman envisioned using the skin of inmates his dermatology drug trials, trials for anti-obesity drugs, viral infections, and bacterial infections, wrote Mr. Hornblum.

All kinds of tests, foot powder, eye drops, face creams, underarm deodorant, toothpaste, liquid diets, were used, leaving inmates scarred and often suffering. Dr. Klingman reportedly declared, All I saw before me were acres of skin It was like a farmer seeing a fertile field for the first time, according to the book.

In 1979, the Philadelphia Inquirer disclosed that Holmesburg inmates had been used as guinea pigs to test whether mind-altering drugs were useful as Army weapons. In 1981 the paper reported that inmates had been dosed with dioxin to test the herbicides effects on humans.

In American Mengele: Human Radiation Experiments, Ryan Grimm detailed what he called experiments more horrible than Tuskegee. He wrote about experiments conducted by Dr. Eugene L. Saenger at Cincinnati General Hospital from 1960 to 1972. The Department of Defense paid him, and several government agencies used his findings.

What makes radiation experiments like Saengers more horrible than those at Tuskegee is that, in these cases, doctors were not merely watching an already existing disease take its course. Instead, Saenger deliberately injected hundreds of people with potentially lethal doses of radiation, knowing that most of them would die rather quickly, wrote Mr. Grimm.

At least 89 people are acknowledged to have died due to Saengers treatment, although the number is likely well above 200. Dr. Saenger even copped to the crime and openly defended his actions as necessary preparation for nuclear war.He was never charged with a crime.

His average patient had five years of formal education, an average I.Q. of 89 and 62 percent were Black.

A study conducted in part by researchers from the Maryland Center for Health Equity at the University of Maryland-College Park, found many Blacks dont get flu shots because they dont trust the vaccine.

Blackdoctors.org reported 58 percent of respondents to their survey would not take a Covid-19 vaccination as soon as it is available. Fifty-eight percent said no to the vaccine, 22 percent reported they would take the vaccine but had concerns. Eighty percent respondents either said no or had concerns about taking a Covid-19 vaccine, citing mistrust of the health care system.

Read more:
We Can't Trust You: Experimentation, Exploitation and the Hidden History of American Medical Abuses - Final Call News - FinalCall.com News

Recommendation and review posted by Bethany Smith

A biotech company spun out of the University of Edinburgh will utilise research to develop new gene therapies to target different types of cancer.

The company, Cellinta Limited, was born out of research from scientists at the University of Edinburgh, and received funding through investments from SV Health Investors and Cancer Research UK.

The funding will be used to develop a pipeline of highly selective gene therapies targeting cancer stem cells in a variety of solid tumour types.

It will draw on research led by Professor Steven Pollard at the University of Edinburgh, which delved into stem cell biology, synthetic biology and cancer genomics.

Cellinta has entered into a collaborative research agreement with the University, and retains the option to license intellectual property developed from research conducted there.

Professor Pollard will join the Cellinta team as scientific founder and a senior adviser, while Dr Soraya Bekkali will take the helm as chief executive officer of the new company.

I am delighted to be leading such an exciting company, said Dr Bekkali.

Cellintas approach offers the opportunity to deliver combinations of therapies selectively to cancer stem cells, bypassing the limitations of traditional treatments which often target single genes or redundant signalling pathways, she added.

Meanwhile, Mike Ross managing partner at London-based SV Health Investors has been appointed chairman of Cellinta.

Cellinta represents a unique opportunity to build a leading company based on exciting and innovative science, with the potential to develop first-in-class therapies, said Ross.

We are delighted with the progress the company has made and extremely pleased to appoint Soraya, who has deep experience in gene therapy across various therapeutic areas, as CEO. We look forward supporting Cellinta in its progress as a pioneer in the field, he added.

Read the rest here:
University of Edinburgh spinout Cellinta will develop gene therapies for cancer - PharmaTimes

Recommendation and review posted by Bethany Smith

Gene Therapy Market - Snapshot

Introduction of new production, availability of reimbursement together with high occurrences of cancer are estimated to propel growth of the global gene therapy market in the years to come. Gene therapy refers to an experimental technique, which utilizes genes for the prevention and treatment of various diseases. It is expected that in the near future, this technology could assist doctors to place a gene into the cells of a patient for the purpose of his treatment. This therapy could be used as an alternative to surgery or drugs. Scientists are examining various approaches to this therapy, which could comprise

Gene therapy has emerged as a promising treatment option for a large number of diseases such as certain viral infections, certain cancers, and inherited disorders. This factor is likely to work in favor of the global gene therapy market in the years to come.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1838

Progress in Gene-editing and Genomics Tools to Stoke Demand of Gene Therapy

CAR T-cell use has recently garnered considerable attention from the sponsors following the exhibition of its immense promise in the treatment of several diseases. The promising future of CAR T-cell is estimated to amplify the growth opportunities of the global gene therapy market. Sponsors hail CAR T-cell use as a brand new business model of the future.

In the pipeline of pharmaceutical industry, gene therapy account for a considerable share and this trend is likely to continue in the years to come. In addition, significant advancement has been made in the fields of cellular and molecular biology is likely to fuel growth of the global gene therapy market in the years to come. rapid technological progress made in the gene-editing and genomics tools are further estimated to drive the demand for gene therapy.

Global Gene Therapy Market Snapshot

Expanding at a stellar, double-digits CAGR (Compound Annual Growth Rate) of 40% over the forecast period of 2018 to 2026, the global gene therapy market is a dizzying trajectory, marking out a rosy landscape for players operating in the playfield. As per a Transparency Market Research report, based on extensive primary and secondary research, states that over the period states, the market would accrue a worth of USD 5164.03 million a steep and impressive increase from the USD 17 million worth noted in 2017.

Request for Analysis of COVID19 Impact on Gene Therapy Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1838

Fixing defective genes via introduction of new and healthy ones to fix severe genetic and chronic disorders is seeing an upward curve in demand for reasons of improved medical outcomes, major leaps in terms of technological advancement and minimal die-effects as compared to alternatives. Some of the most significant alternatives include surgery, and drug use.

Some of the most significant factors that the analysts of the report note include focused efforts towards marketing and commercialization, and a slew of approvals of new products hitting the global gene therapy market. Additionally, there are factors such as growing demand experienced for this treatment by a large pool of patients.

It is pertinent to note here that the global gene therapy market is consolidated and is dependent on clinincal research and development of the highest standards in order to chart growth. And, some of the players that operate the market landscape, and are into significant research projects include Gilead Sciences, Inc., Novartis AG, Sibiono GeneTech Co. Ltd., Spark Therapeutics, Inc., CELGENE CORPORATION, and Orchard Therapeutics Limited.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=1838

Yescarta to Dominate Global Gene Therapy Market over the Forecast Period

The global gene therapy market report by TMR is segmented based on type, application, and region. The former includes the only five products that have been approved so far for commercial use. These include Gendicine, Yescarta, Strimvelis, Kymriah, and Luxturna. Riding the first mover benefits, Yescarta helf the dominant position in the market in 2017, and the trend will continue, adding more worth to the sub-segment. This is the product that brought out the initial CAR T therapy in the market for large B-cell lymphoma that relapse.

It is worth noting here that as per the global gene therapy market report, the high incidence of DLBCL and massive commercialization efforts directed towards Yescarta, particularly in Europe, will contribute positively and significantly to the overall growth of the global gene therapy market. The other sub-segment to make a mark over the global gene therapy market landscape will be Luxturna, owing to rising awareness levels and massive efforts towards comercialization.

Buy Gene Therapy Market Report -https://www.transparencymarketresearch.com/checkout.php?rep_id=1838<ype=S

Europe to be Ahead of the Global Gene Therapy Market Growth Curve over the Forecast Period

The global gene therapy markets regional segmentation includes incisive growth insights into some of the most significant areas that will shape up the overall growth in the market. These include North America, Europe, and Rest of the World. Researchers involved with the preparation of report claim that a massive chunk of about 40% would be accounted for by Europe over the forecast period. Some of the factors backing-up the market dominance of the region include high incidence of non Hodgkin lymphoma and increase in number of treatment centers into gene therapy.

This growth would be followed by North America region, owing to huge contributions from the United States of America which witnesses about 7500 cases of refractory DLBCL each year. These are ones that qualify for the CAR T therapy.

More Trending Reports by Transparency Market Research:

Neonatal Phototherapy Market: https://www.transparencymarketresearch.com/neonatal-phototherapy-market.html

Proteinase K Market: https://www.transparencymarketresearch.com/proteinase-k-market.html

Swine Respiratory Diseases Treatment Market: https://www.transparencymarketresearch.com/swine-respiratory-diseases-treatment-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Original post:
Gene Therapy Market Progress in Gene-editing and Genomics Tools to Stoke Demand of Gene Therapy - BioSpace

Recommendation and review posted by Bethany Smith

The global Cancer Gene Therapy market study encloses the projection size of the market both in terms of value (Mn/Bn US$) and volume (x units). With bottom-up and top-down approaches, the report predicts the viewpoint of various domestic vendors in the whole market and offers the market size of the Cancer Gene Therapy market. The analysts of the report have performed in-depth primary and secondary research to analyze the key players and their market share. Further, different trusted sources were roped in to gather numbers, subdivisions, revenue and shares.

The research study encompasses fundamental points of the global Cancer Gene Therapy market, from future prospects to the competitive scenario, extensively. The DROT and Porters Five Forces analyses provides a deep explanation of the factors affecting the growth of Cancer Gene Therapy market. The Cancer Gene Therapy market has been broken down into various segments, regions, end-uses and players to provide a clear picture of the present market situation to the readers. In addition, the macro- and microeconomic aspects are also included in the research.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/2988

Some of the major companies operating in the global cancer gene therapy market are Cell Genesys, Advantagene, GenVec, BioCancell, Celgene and Epeius Biotechnologies. Other leading players in cancer gene therapy market include Introgen Therapeutics, ZIOPHARM Oncology, MultiVir and Shenzhen SiBiono GeneTech

Key points covered in the report

Purchase reports at discounted prices!!! Offer valid till midnight!!!

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/2988

The Cancer Gene Therapy market research covers an exhaustive analysis of the following data:

The Cancer Gene Therapy market research addresses critical questions, such as

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/2988

The global Cancer Gene Therapy market research considers region 1 (Country 1, country 2), region 2 (Country 1, country 2) and region 3 (Country 1, country 2) as the important segments. All the recent trends, such as changing consumers demand, ecological conservation, and regulatory standards across different regions are covered in the report.

The rest is here:
Increase in the Adoption of Cancer Gene Therapy to Propel the Growth of the Cancer Gene Therapy Market Between2020 - The Daily Chronicle

Recommendation and review posted by Bethany Smith

Management to Highlight Progress in Bone Marrow Transplant (BMT) and Chimeric Antigen Receptor T Cell (CAR T) Business Collaborations

Tel Aviv, Israel, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of cells facilitating safer and more efficacious cell and gene therapies, today announced that the leadership will be presenting at the Cell & Gene Meeting on the Mesa, which is being held from October 12th 16th. In addition to providing an overview of the Company, the management team will provide a progress update on the clinical and development programs and an overview of the Companys business strategy. Management will be virtually meeting cell and gene therapy companies to support collaborations.

This is one of the most prestigious meetings for our industry, and despite it being virtual this year due to the COVID-19 pandemic, it will not dampen our enthusiasm commented Dr. Yarkoni. We have successfully adjusted our operations, and we continue to make significant progress with our Israel and U.S.-based clinical trials. We are also taking meaningful steps to accelerate nearer-term revenue opportunities as we are collaborating with several partners that are looking to leverage our technology platform to help improve their products, especially in high-growth areas such as CAR T, NK (natural killers) and MSCs. We are looking forward to sharing the progress we have made and also look forward to meeting with current and potential partners developing cell and gene therapies.

To schedule a meeting with the Companys Chief Executive Officer, Dr. Shai Yarkoni or Chief Operating Officer, Amos Ofer, please request a meeting through the meeting portal and/or contact the Company direct at shai@cellect.co or amoso@cellect.co. The presentation will be available on the Companys website prior to the commencement of the meeting. The Cell & Gene Meeting on the Mesa is the sectors foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures.

About Cellect Biotechnology Ltd.

Cellect Biotechnology (APOP) has developed a breakthrough technology, for the functional selection of cells that aims to improve the robustness, safety and efficacy of a variety of cell and gene therapies. The Companys technology can be used by researchers, clinical community and pharma companies in a wide variety of applications including next generation Car T, NK, MSC and gene therapies.

The Company is also developing its own product that is an improved BMT which is in a current clinical trial for cancer treatment.

Forward Looking Statements

This press release contains forward-looking statements about the Companys expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as believe, expect, intend, plan, may, should, could, might, seek, target, will, project, forecast, continue or anticipate or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss Cellects expectations regarding timing of the commencement of its planned U.S. clinical trial and its plan to reduce operating costs. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Companys history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Companys ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; the Companys ability to obtain regulatory approvals; the Companys ability to obtain favorable pre-clinical and clinical trial results; the Companys technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Companys clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Companys ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Companys industry; unforeseen scientific difficulties may develop with the Companys technology; the Companys ability to retain or attract key employees whose knowledge is essential to the development of its products; and the Companys ability to pursue any strategic transaction or that any transaction, if pursued, will be completed. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading Risk Factors in Cellect Biotechnology Ltd.s Annual Report on Form 20-F for the fiscal year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SECs website, http://www.sec.gov, and in the Companys periodic filings with the SEC.

ContactCellect Biotechnology Ltd.Eyal Leibovitz, Chief Financial Officerwww.cellect.co+972-9-974-1444

Or

EVC Group LLCMichael Polyviou(732) 933-2754mpolyviou@evcgroup.com

More here:
Cellect Biotechnology to Present at the 2020 Cell & Gene Meeting on the Mesa - GlobeNewswire

Recommendation and review posted by Bethany Smith

Market Study Report, LLC, adds a thorough analysis of the ' Hemophilia Gene Therapy market', offering a comprehensive report emphasizing every vital aspect of the business vertical. The study has collectively presented refined data characterized by market valuation, SWOT analysis, market participants, regional segmentation, and revenue forecasts, enabling stakeholders to make logical business decisions.

The research report on Hemophilia Gene Therapy market comprises of driving factors and trends that will impact the industry growth during the forecast period. Thorough examination of market remuneration with reference to regional terrain is entailed in the report. It also mentions the challenges this business sphere will face as well as provide information regarding potential growth prospects. Besides, the report also includes COVID-19 case studies to deliver a better picture of this business sphere to all industry partakers.

Request a sample Report of Hemophilia Gene Therapy Market at:https://www.marketstudyreport.com/request-a-sample/2931028?utm_source=algosonline.com&utm_medium=TS

Pivotal pointers from COVID-19 effect assessment:

Overview of regional terrain:

Other important highlights from the Hemophilia Gene Therapy market report:

Ask for Discount on Hemophilia Gene Therapy Market Report at:https://www.marketstudyreport.com/check-for-discount/2931028?utm_source=algosonline.com&utm_medium=TS

Key features of this report are:

Table of Contents:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-hemophilia-gene-therapy-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

Related Reports:

2. Global Ceiling-Mounted Supply Pendants With Column Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)Read More: https://www.marketstudyreport.com/reports/global-ceiling-mounted-supply-pendants-with-column-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

Read More Reports On: https://www.marketwatch.com/press-release/melamine-market-by-source-product-type-process-and-region-forecast-to-2026-2020-09-21?tesla=y

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

See original here:
Hemophilia Gene Therapy Market Comprehensive Analysis, Growth Forecast from 2020 to 2025 - AlgosOnline

Recommendation and review posted by Bethany Smith

A 2018 analysis of studies looking for genetic variants associated with disease found that under-representation [of minorities] persists: 78% of study participants were of European ancestry, compared to 10% of Asian ancestry and 2% of African ancestry. Other ancestries each represented less than 1% of the total. Several projects, such as H3Africa, are starting to increase participation of under-represented groups, both among participants and among researchers. Large biobanks assembled in Europe and North America, combining biological samples with health-related data, also set sampling targets to increase diversity.

But even when data from minority groups are available, many researchers discard them. Although there can be valid reasons to restrict analyses to a particular population, discarding such data by default is ethically problematic: it worsens under-representation and negates participants efforts to contribute to research.

Funding agencies have taken steps to improve the diversity of participants who are recruited for studies notably, this has led to better representation of women in clinical trials since the 1990s. But agencies have less control over researchers decisions of what to analyse. Scientists are pulled towards statistical convenience and publishing incentives, which can both conflict with the collective goal of greater equity.

There are good reasons to follow precedent: using standard analytical pipelines reduces development cost and the need for extensive validation and explanation. By omitting data, scientists squander an opportunity to build useful knowledge about minority populations.

Read the original post

Read the original:
Asians and Blacks dramatically under-represented in medical research, distorting drug therapy effectiveness - Genetic Literacy Project

Recommendation and review posted by Bethany Smith

Xtalks Life Science Webinars

TORONTO (PRWEB) September 21, 2020

The International Organization for Standardization (ISO) has recently issued its eagerly awaited guidance on the transportation of cells for therapeutic use (ISO 21973). The ISO document is meant to provide general requirements and points to consider for transportation service providers, clients and senders to ensure cell quality, safety and efficacy during the transportation process. This webinar will discuss the key recommendations and changes that interested parties should review and evaluate when planning their clinical and commercial distribution strategies for cell and gene therapies. Some of the elements to be discussed are documentation, traceability, validation and qualification activities, temporary storage, as well as cleaning and disinfection.

Join Robert Jones, Vice President, BioServices, Cryoport Systems in a live webinar on Thursday, October 1, 2020 at 11am EDT (4pm BST/UK).

For more information or to register for this event, visit Addressing the Recent ISO 21973 Guidance: Considerations for Cell and Gene Therapy Distribution.

ABOUT CRYOPORT, INC.

Cryoport, Inc. is redefining temperature controlled supply chain support for the life sciences industry by providing a broad platform of temperature-controlled supply chain solutions, serving the Biopharma, Reproductive Medicine, and Animal Health markets. Our mission is to support life and health on earth by providing reliable and comprehensive solutions for the life sciences industry through our advanced technologies, global supply chain network and dedicated scientists, technicians and supporting team of professionals. Through our purpose-built, proprietary Cryoport Express Shippers; Cryoportal information technology; validated Global Logistics Centers; smart and sustainable temperature-controlled logistics solutions; and biostorage/biobanking services, Cryoport serves clients in life sciences research, clinical trials, and product commercializations. We support life-saving advanced cell and gene therapies and deliver vaccines, protein producing materials, and IVF materials in over 100 countries around the world. For more information, visit http://www.cryoport.com or follow @cryoport on Twitter at http://www.twitter.com/cryoport for live updates.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.comFor information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Read the rest here:
Addressing the Recent ISO 21973 Guidance: Considerations for Cell and Gene Therapy Distribution, Upcoming Webinar Hosted by Xtalks - PR Web

Recommendation and review posted by Bethany Smith

DetailsCategory: DNA RNA and CellsPublished on Tuesday, 22 September 2020 10:38Hits: 206

The comprehensive cancer center has also dosed its first patient in chlorotoxin CAR T cell therapy trial

DUARTE, CA, USA I September 21, 2020 I City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, today announced that it has licensed intellectual property relating to its pioneering chlorotoxin chimeric antigen receptor (CLTX-CAR) T cell therapy to Chimeric Therapeutics Limited, an Australian biotechnology company.

The therapy is currently being used in a phase 1 clinical trial at City of Hope to treat glioblastoma (GBM), a type of brain tumor. The first patient in the trial was recently dosed; Behnam Badie, M.D., chief of City of Hopes Division of Neurosurgery and The Heritage Provider Network Professor in Gene Therapy, is leading this innovative, first-of-its-kind trial.

Chimeric has acquired the exclusive worldwide rights to develop and commercialize certain patents relating to City of Hopes CLTX-CAR T cells, as well as to further develop the therapy for other cancers.

City of Hope is excited to enter into this agreement with Chimeric as it supports our innovative research in CAR T cell therapy and our commitment to extend these therapies to more patients, particularly those with GBM and other solid tumors that are difficult to treat, said Christine Brown, Ph.D., The Heritage Provider Network Professor in Immunotherapy and deputy director of City of Hopes T Cell Therapeutics Research Laboratory. Chimeric shares our goal of providing effective CAR T cell therapies to more patients with current unmet medical needs.

Led by Brown and Michael Barish, Ph.D., chair of City of Hopes Department of Developmental and Stem Cell Biology, and Dongrui Wang, Ph.D., a recent graduate of City of Hopes Irell & Manella Graduate School of Biological Sciences, the team developed and tested the first CAR T cell therapy using CLTX, a component of scorpion venom, to direct T cells to target brain tumor cells. The research was published this past March in Science Translational Medicine.

Chimeric is excited to join City of Hope in its quest to find more effective cancer therapies. This is an exceedingly rare opportunity to acquire a promising technology in one of the most exciting areas of immuno-oncology today, said Paul Hopper, executive chairman of Chimeric. Furthermore, the CLTX-CAR T cell therapy has completed years of preclinical research and development, and recently enrolled its first patient in a phase 1 clinical trial for brain cancer.

CARs commonly incorporate a monoclonal antibody sequence in their targeting domain, enabling CAR T cells to recognize antigens and kill tumor cells. In contrast, the CLTX-CAR uses a synthetic 36-amino acid peptide sequence first isolated from death stalker scorpion venom and now engineered to serve as the CAR recognition domain.

In this recent study, City of Hope researchers used tumor cells in resection samples from a cohort of patients with GBM to compare CLTX binding with expression of antigens currently under investigation as CAR T cell targets. They found that CLTX bound to a greater proportion of patient tumors, and cells within these tumors.

CLTX binding included the GBM stem-like cells thought to seed tumor recurrence. Consistent with these observations, CLTX-CAR T cells recognized and killed broad populations of GBM cells while ignoring nontumor cells in the brain and other organs. The study team demonstrated that CLTX-directed CAR T cells are highly effective at selectively killing human GBM cells without off-tumor targeting and toxicity in cell-based assays and in animal models.

City of Hope, a recognized leader in CAR T cell therapies for GBM and other cancers, has treated more than 500 patients since its CAR T program started in the late 1990s. The institution continues to have one of the most comprehensive CAR T cell clinical research programs in the world it currently has 30 ongoing CAR T cell clinical trials, including CAR T cell trials for HER-2 positive breast cancer that has spread to the brain, and PSCA-positive bone metastatic prostate cancer. It was the first and only cancer center to treat GBM patients with CAR T cells targeting IL13R2, and the first to administer CAR T cell therapy locally in the brain, either by direct injection at the tumor site, through intraventricular infusion into the cerebrospinal fluid, or both. In late 2019, City of Hope opened a first-in-human clinical trial for patients with recurrent GBM, combining IL13R2-CAR T cells with checkpoint inhibitors nivolumab, an anti-PD1 antibody, and ipilimumab, blocking the CTLA-4 protein.

Both an academic medical center and a drug development powerhouse, City of Hope is known for creating the technology used in the development of human synthetic insulin and numerous breakthrough cancer drugs. Its unique research and development hybrid of the academic and commercial creates an infrastructure that enables City of Hope researchers to submit an average of 50 investigational new drug applications to the U.S. Food and Drug Administration each year. The institution currently holds more than 450 patent families.

"City of Hope is delighted to license this technology to Chimeric, said Sangeeta Bardhan Cook, Ph.D., City of Hope director of the Office of Technology Licensing. We are impressed with the ability of their executive team to push and bring therapies to market expeditiously. At City of Hope, our mission is to transform the future of health care. We believe Chimeric has the vision to offer innovative therapies to cancer patients.

About City of Hope

City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hopes translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin and numerous breakthrough cancer drugs are based on technology developed at the institution. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope has been ranked among the nations Best Hospitals in cancer by U.S. News & World Report for 14 consecutive years. Its main campus is located near Los Angeles, with additional locations throughout Southern California. For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.

SOURCE: City of Hope

Read more from the original source:
City of Hope Enters Licensing Agreement With Chimeric to Develop Its Pioneering Chlorotoxin CAR T Cell Therapy | DNA RNA and Cells | News Channels -...

Recommendation and review posted by Bethany Smith